RESEARCH POSTER PRESENTATIONS SESSION III: Tuesday, 6 November 2012

Click on the topic below to view posters

SESSION III – TUESDAY, 6 NOVEMBER
SET-UP: Tuesday, 6 November 2012, 8:30 – 8:45
POSTER DISPLAY HOURS: Tuesday, 6 November 2012, 8:45 – 13:45
POSTER AUTHOR DISCUSSION HOUR: Tuesday, 6 November 2012, 12:45 – 13:45
DISMANTLE: Tuesday, 6 November 2012, 13:45

HEALTH CARE DECISION-MAKER’S CASE STUDIES Health Care Decision-Maker’s Case Study Abstracts

PCASE1

A COMPARISON OF THE NICE AND IQWIG/G-BA ASSESSMENTS OF TICAGRELOR FOR ACS

 

George E1, Sidhu R2, Kaiser T3, Schüler YB3, Wieseler B3
1National Institute for Health and Clinical Excellence, Holborn, London, UK, 2National Institute for Health and Clinical Excellence, London, UK, 3Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Köln, Germany

PCASE2

LIMITATIONS OF EGYPTIAN CURRENT PRICING SYSTEM

 

ElSisi G1, Botros A1, Sharaf Eldeen M2
1Central Administration for Pharmaceutical Affairs, Cairo, Egypt, 2Nasser Institute, Cairo, Egypt

PCASE3

WHAT IS THE ACTUAL COST OF HOSPITALIZATION FOR A PATIENT TREATED WHIT A TRANSCATHETER VALVE IMPLANT?

 

Brami M, Voisin L
Agence Technique de l'Information sur l'Hospitalisation, Paris, France

PCASE4

ECONOMIC IMPACT OF PATHOLOGICAL FRACTURE AVOIDED IN ONCOLOGY PATIENTS IN A HEALTH INSURANCE PROVIDER IN BRAZIL

 

Tanaka E, Mariano da Costa ES, Santos G, Westhphalen C, Kotze O
Curitiba City Health Institute, CURITIBA, PARANÁ STATE, Brazil

PCASE5

BIOSIMILAR HEMATOPOIETIC GROWTH FACTORS IN THE PUBLIC HOSPITALS OF PARIS : TRADE-OFFS BETWEEN ECONOMIC GOALS AND EVIDENCE BASED MEDICINE

 

Bocquet F1, Paubel P2, Fusier I3, Cordonnier AL3, Poisson N3, Le Pen C1, Sinègre M3
1Dauphine University, Paris, France, 2Paris Descartes University, Paris, France, 3General Agency of Equipment and Health Products (AGEPS), AP-HP, Paris, France

SESSION III – TUESDAY, 6 NOVEMBER
SET-UP: Tuesday, 6 November 2012, 8:30 – 8:45
POSTER DISPLAY HOURS: Tuesday, 6 November 2012, 8:45 – 13:45
POSTER AUTHOR DISCUSSION HOUR: Tuesday, 6 November 2012, 12:45 – 13:45
DISMANTLE: Tuesday, 6 November 2012, 13:45

SURGERY – Clinical Outcomes Studies

PSU1

3-YEAR REAL-WORLD OUTCOMES WITH THE SWEDISH ADJUSTABLE GASTRIC BANDTM IN FRANCE

 

Ribaric G
Johnson & Johnson, Norderstedt, Germany

PSU2

THE INCIDENCE OF COMPLICATIONS AFTER ITS THYROIDECTOMY IN PATIENTS WITH THYROID CANCER IN KOREA : USING HEALTH CLAIM DATABASE

 

Hyun MK1, Kim J1, Kwon JW1, Park YJ2
1National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea, 2Seoul National University College of Medicine, Seoul, South Korea

PSU3

PROLONGED EFFECTIVENESS OF CORONARY ARTERY BYPASS SURGERY VERSUS DRUG-ELUTING STENTS IN DIABETICS WITH MULTI-VESSEL DISEASE: AN UPDATED META-ANALYSIS

 

Ariyaratne TV1, Ademi Z2, Yap CH3, Billah B1, Rosenfeldt F4, Yan BP5, Reid CM1
1Monash University, Melbourne, Victoria, Australia, 2University of Melbourne, Melbourne, Australia, 3Geelong Hospital & Monash University, Geelong, Victoria, Australia, 4Alfred Hospital & Monash University, Melbourne, Victoria, Australia, 5Prince of Wales Hospital & Monash University, Hong Kong, Hong Kong, China

PSU4

REGIONAL VARIATION IN ANGIOGRAM USE FOR PATIENTS WHO UNDERWENT CORONARY ARTERY BYPASS GRAFT SURGERY

 

Baser O1, Burkan A2, Baser E3, Koselerli R2, Ertugay E2, Altinbas A4
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2Social Security Institution, Ankara, Turkey, 3STATinMED Research, Istanbul, MI, Turkey, 4Dýskapý Yýldýrým Beyazýt Education and Research Hospital, Ankara, Turkey

PSU5

BARIATRIC SURGERY FROM THE PERSPECTIVE OF BRAZILIAN NATIONAL HEALTH SYSTEM (SUS)

 

Freitas MG1, Souza KM2, Silva MT3, Elias FTS4
1Brazilian Ministry of Health, Brasilia, Distrito Federal, Brazil, 2Brazilian Ministry of Health, Belo Horizonte, Minas Gerais, Brazil, 3Brazilian Ministry of Health, Brasília, DF, Brazil, 4Ministry of Health of Brazil, Brasilia, Distrito Federal, Brazil

PSU6

WITHDRAWN

 

 

PSU7

SEASONAL PERIODICITY OF SECONDARY HIP REPLACEMENT AFTER FEMORAL NECK FRACTURES WITH REDUCTION INTERNAL SCREW FIXATION AGED OVER 60

 

Sebestyén A1, Gajdácsi J2, Patzai B3, Molics B3, Varga S3, Sándor J4, Boncz I3
1South-Trasdanubian Regional Health Insurance Fund Administration, Pécs, Hungary, 2National Health Insurance Fund Administration, Budapest, Hungary, 3University of Pécs, Pécs, Hungary, 4University of Debrecen, Debrecen, Hungary

SURGERY – Cost Studies

PSU8

BUDGET IMPACT ANALYSIS OF ANTI-BACTERIAL SUTURE USE IN APPENDECTOMY PROCEDURES IN SPAIN

 

Pobre MA1, Espallardo O2
1Johnson & Johnson Medical, Madrid, Spain, Spain, 2Johnson & Johnson Medical, Madrid, Madrid, Spain

PSU9

BUDGET IMPACT OF AUTOGRAFT HARVEST, BONE GRAFT SUPPLEMENTS AND ORTHOBIOLOGIC BONE GRAFT SUBSTITUTE IN FOOT AND ANKLE FUSION PROCEDURES

 

Abidi NA1, Carlson A2, Harris E3
1Santa Cruz Orthopaedic Institute, Capitola, CA, USA, 2Data Intelligence Consultants, LLC, Eden Prairie, MN, USA, 3BioMimetic Therapeutics, Inc., Franklin, TN, USA

PSU10

COSTS OF CARDIOVASCULAR READMISSIONS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: DATA FROM A LARGE MULTI-CENTRE AUSTRALIAN REGISTRY

 

Ariyaratne TV1, Ademi Z2, Duffy SJ3, Andrianopoulos N1, Billah B1, Brennan AL1, Clark DJ4, New G5, Black A6, Ajani AE7, Yan BP8, Reid CM1
1Monash University, Melbourne, Victoria, Australia, 2University of Melbourne, Melbourne, Australia, 3Alfred Hospital & Monash University, Melbourne, Victoria, Australia, 4Austin Hospital, Melbourne, Victoria, Australia, 5Box Hill Hospital, Melbourne, Victoria, Australia, 6Geelong Hospital, Geelong, Victoria, Australia, 7Royal Melbourne Hospital, Melbourne, Victoria, Australia, 8Prince of Wales Hospital & Monash University, Hong Kong, Hong Kong, China

PSU11

MEDICAL COSTS COMPARISON BETWEEN INTERNAL FIXATION AND ARTHOPLASTY IN PATIENTS WITH HIP FEMORAL NECK FRACTURES

 

Song X1, Shi N1, Yurgin N2, Varker H1, Dent R2, Bhandari M3
1Truven Health Analytics, Cambridge, MA, USA, 2Amgen Inc., Thousand Oaks, CA, USA, 3McMaster University, Hamilton, ON, Canada

PSU12

MINIMALLY INVASIVE SURGERY IN SPINAL FUSION : CLINICAL AND ECONOMICAL IMPACT FROM HOSPITAL PERSPECTIVE

 

Charles YP1, Vouaillat H2, Marcaud M3, Ihara Z4
1Hôpitaux Universitaires de Strasbourg, Strasbourg, France, 2Clinique des Cèdres, Echirolles, France, 3Medtronic France SAS, Boulogne-Billancourt, France, 4Medtronic International, Tolochenaz, Switzerland

PSU13

SURVIVAL AND COST COMPARISON OF BALLOON-KYPHOPLASTY AND VERTEBROPLASTY USING GERMAN CLAIMS DATA

 

Lange A1, Kasperk C2, Braun S3
1Leibniz University Hannover, Hannover, Germany, 2University of Heidelberg, Heidelberg, Germany, 3HERESCON GmbH, Hannover, Germany

PSU14

ECONOMIC IMPACT OF SCOLIOSIS IN CANADA: A RAMQ DATABASE ANALYSIS

 

Lachaine J1, Moreau A2, Beauchemin C1, Mathurin K1
1University of Montreal, Montreal, QC, Canada, 2CHU Sainte-Justine Research Center, Montreal, QC, Canada

PSU15

CLINICAL AND ECONOMIC BURDEN OF ANASTOMOTIC LEAKS AFTER COLORECTAL SURGERIES

 

Lim S1, Hammond J1, Wan Y2, Gao X2, Patkar A1
1Ethicon, Inc., Somerville, NJ, USA, 2Pharmerit, Bethesda, MD, USA

PSU16

HIGH COST PATIENTS FOR CARDIAC SURGERY AND HOSPITAL QUALITY IN TURKEY

 

Baser O1, Burkan A2, Baser E3, Koselerli R2, Ertugay E2, Altinbas A4
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2Social Security Institution, Ankara, Turkey, 3STATinMED Research, Istanbul, MI, Turkey, 4Dýskapý Yýldýrým Beyazýt Education and Research Hospital, Ankara, Turkey

PSU17

THE COST OF SURGICAL PROCEDURE TO REMOVE ADHESIONS ABDOMEN OR PELVIS IN THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM

 

Ferreira CN1, Follador W2, Paloni EDMP1, Peralta CEP3, Bonachela F4
1ORIZON - Companhia Brasileira de Gestão de Serviços, Sao Paulo, Sao Paulo, Brazil, 2Sanofi, São Paulo , São Paulo , Brazil, 3Orizon, Barueri, SAO PAULO, Brazil, 4Orizon, SAO PAULO, SAO PAULO, Brazil

PSU18

ASSESSMENT OF THE RESOURCE USE AND COSTS ASSOCIATED WITH PARATHYROIDECTOMY SURGERY FOR SECONDARY HYPERPARATHYROIDISM IN END STAGE RENAL DISEASE IN THE UNITED KINGDOM

 

Pockett RD1, Cevro E2, Scott-Coombes D3, Chamberlain GH1
1Swansea University, Cardiff, UK, 2Amgen UK & Ireland, Uxbridge, UK, 3University Hospital of Wales, Cardiff, UK

PSU19

DOES THE NOVEL RENAL MARKER NGAL (NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN) RESULT IN COST SAVINGS IN PATIENTS WITH RENAL IMPAIRMENT FOLLOWING CARDIAC SURGERY?

 

Stanger O, Bacher B
Salzburg Medical University, Salzburg, Austria

PSU20

A COST-EFFECTIVENESS ANALYSIS OF MINIMALLY INVASIVE VERSUS OPEN SURGERY TECHNIQUES FOR LUMBAR SPINE FUSION

 

Vertuani S1, Ihara Z2, Musayev A1, Nilsson J3
1OptumInsight, Stockholm, Stockholm, Sweden, 2Medtronic International, Tolochenaz, Tolochenaz, Switzerland, 3OptumInsight, Stockholm, Sweden

PSU21

SENTINEL LYMPH NODE BIOPSY LESS EXPENSIVE THAN AXILLARY LYMPH NODE DISSECTION IN EARLY BREAST CANCER STAGING

 

Raimond V
Haute Autorite de sante, Saint-Denis La Plaine, France

SURGERY – Patient-Reported Outcomes & Patient Preference Studies

PSU22

HEALTH-RELATED QUALITY OF LIFE IN PROSTATE CANCER - COMPARISON OF ROBOT-ASSISTED AND OPEN SURGERY

 

Roine R1, Bergius S2, Muhonen T3, Sintonen H4, Taari K5
1Helsinki and Uusimaa Hospital District, Helsinki, Finland, 2University of Helsinki and Amgen AB, Espoo, Finland, 3Helsinki University Hospital and Amgen AB, Espoo, Finland, 4University of Helsinki, Helsinki, Finland, 5Helsinki University Hospital, Helsinki, Finland

PSU23

WOMEN'S PREFERENCES FOR BREAST RECONSTRUCTION: A STUDY USING A DISCRETE CHOICE EXPERIMENTS

 

Tang C
Taipei Medical University, Taipei, Taiwan

PSU24

THE EQUIVALENCE OF REMOTE ELECTRONIC AND PAPER COLLECTION OF PATIENT REPORTED OUTCOMES (PROS): A CROSSOVER TRIAL

 

Griffiths-Jones W, Fern ED, Norton MR, Williams DH
Royal Cornwall Hospital, Truro, Cornwall, UK

PSU25

BALLOON KYPHOPLASTY INCREASES QUALITY OF LIFE IN CANCER PATIENTS WITH VERTEBRAL COMPRESSION FRACTURES

 

Olafsson G1, Mesterton J2, Berenson JR3, Vrionis F4, Alvares L5
1Quantify Research, Stockholm, Stockholm, Sweden, 2Quantify Research, Stockholm, Sweden, 3Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, USA, 4H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA, 5Medtronic International Trading Sarl, Tolochenaz, VD, Switzerland

PSU26

HEALTH-RELATED QUALITY OF LIFE IN FAMILIAL AMYLOIDOTIC POLYNEUROPATHY BEFORE AND AFTER LIVER TRANSPLANTATION: A SYSTEMATIC LITERATURE REVIEW

 

Amaral LM1, Fernandes RA1, Vasconcellos JF1, Takemoto M1, Fujii RK2, Furlan F3, Mould J4
1ANOVA - Knowledge Translation, Rio de Janeiro, RJ, Brazil, 2Pfizer, Inc., São Paulo, São Paulo, Brazil, 3Pfizer, Inc., São Paulo, SP, Brazil, 4Pfizer, New York, NY, USA

SURGERY – Health Care Use & Policy Studies

PSU27

LIVER TRANSPLANTATION IN FAMILIAL AMYLOID POLYNEUROPATHY IN BRAZIL: DEMOGRAPHIC AND CLINICAL DATA COMPARED TO FAP WORLD TRANSPLANT REGISTRY

 

Fernandes RA1, Amaral LM1, Takemoto MMS1, Takemoto M1, Vasconcellos JF1, Cukier FN1, Fujii RK2, Furlan F3, Mould J4
1ANOVA - Knowledge Translation, Rio de Janeiro, RJ, Brazil, 2Pfizer, Inc., São Paulo, São Paulo, Brazil, 3Pfizer, Inc., São Paulo, SP, Brazil, 4Pfizer, New York, NY, USA

PSU28

RETROSPECTIVE ANALYSIS OF LIVER TRANSPLANTATION IN BRAZIL

 

Fernandes RA1, Amaral LM1, Takemoto MMS1, Takemoto M1, Vasconcellos JF1, Cruz RB1, Cukier FN1, Furlan F2, Fujii RK3, Mould J4
1ANOVA - Knowledge Translation, Rio de Janeiro, RJ, Brazil, 2Pfizer, Inc., São Paulo, SP, Brazil, 3Pfizer, Inc., São Paulo, São Paulo, Brazil, 4Pfizer, New York, NY, USA

PSU29

FRENCH SURVEY ON THE MANAGEMENT OF ANEMIA AND IRON SUPPLEMENTATION IN PATIENTS IN ELECTIVE ORTHOPEDIC SURGERY

 

Rosencher N1, Lasocki S2, Mammar N3, Zakin L4, Mahi L4, Lienhart A5
1Hôpital Cochin, Paris, Ile de France, France, 2Centre Hospitalier d'Angers, Angers, Pays de Loire, France, 3Vifor France SA, Neuilly-sur-Seine, Ile de France, France, 4Vifor Pharma International, Neuilly-sur-Seine Cedex, Ile de France, France, 5Hôpital Saint-Antoine, Paris, Ile de France, France

PSU30

EFFECTS OF DIFFERENT CLINICAL PRACTICES OF LAPAROSCOPIC SURGERY FOR ENDOMETRIOSIS TREATMENT ON COST OF THERAPY

 

Parali E1, Deger C1, Marmarali B1, Memis SA1, Sumer F1, Karakeben K1, Kayadibinli M2
1Bayer Türk, Istanbul, Turkey, 2STATinMED Research, Istanbul, Turkey

PSU31

THE ASSOCIATION BETWEEN DEGENERATIVE DISK DISEASE AND OUTCOMES AMONG PATIENTS UNDERGOING LUMBAR FUSION SURGERY

 

Lage MJ1, Kemner JE2, McCormack M2, Treglia M1
1HealthMetrics Outcomes Research, Delray Beach, FL, USA, 2Medtronic Spinal & Biologics, Memphis, TN, USA

PSU32

A COMPARISON OF RESOURCE UTILIZATION AND MEDICAL CHARGES AMONG LUMBAR INTERBODY FUSION SURGICAL PATIENTS WITH AND WITHOUT REVISION

 

Kemner JE1, Lage MJ2, Treglia M2
1Medtronic Spinal & Biologics, Memphis, TN, USA, 2HealthMetrics Outcomes Research, Delray Beach, FL, USA

PSU33

CHARACTERISTICS AND BURDEN OF TUBEROUS SCLEROSIS COMPLEX: RESULTS OF A PATIENT AND CAREGIVER SURVEY IN THE UNITED STATES

 

Pashos CL1, Rentz A2, Liu J3, Pelletier C4, Prestifilippo J5, Nakagawa J6, Frost MD7, Dunn DW8, Wheless JW9
1United BioSource Corporation, Lexington, MA, USA, 2United BioSource Corporation, Bethesda, MD, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4Novartis, Florham Park, NJ, USA, 5Novartis, East Hanover, NJ, USA, 6Tuberous Sclerosis Alliance, Silver Spring, MD, USA, 7Minnesota Epilepsy Group, PA, St. paul, MN, USA, 8Riley hospital for Children, Indianapolis, IN, USA, 9Le Bonheur Children's Hospital, Memphis, TN, USA

PSU34

EPIDEMIOLOGICAL MODELING OF PATIENT SURVIVAL AFTER LIVER TRANSPLANTATION IN GERMANY

 

Jugl S, Langsdorf V, Schüle S
Novartis Pharma GmbH, Nuremberg, Bavaria, Germany

PSU35

EPIDEMIOLOGICAL MODELING OF PATIENT SURVIVAL AFTER HEART TRANSPLANTATION IN GERMANY

 

Jugl S, Langsdorf V, Schüle S
Novartis Pharma GmbH, Nuremberg, Bavaria, Germany

PSU36

EVIDENCE BASED MEDICINE: A CASE STUDY OF ITS APPLICATION TO INNOVATIVE SURGICAL PROCEDURES IN THE UNITED KINGDOM

 

Mauskopf J1, Beach W2, McIntyre L3, Bhattacharyya SK4, Higgins L5, Mordin M6, Copley-Merriman K6
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Tuckahoe Orthopaedic Associates, Henrico, VA, USA, 3Westchester Orthopaedic Associates, White Plains, NY, USA, 4DePuy Mitek, Inc., Raynham, MA, USA, 5Brigham and Women's Hospital; Harvard Medical School, Boston, MA, USA, 6RTI Health Solutions, Ann Arbor, MI, USA

SESSION III – TUESDAY, 6 NOVEMBER
SET-UP: Tuesday, 6 November 2012, 8:30 – 8:45
POSTER DISPLAY HOURS: Tuesday, 6 November 2012, 8:45 – 13:45
POSTER AUTHOR DISCUSSION HOUR: Tuesday, 6 November 2012, 12:45 – 13:45
DISMANTLE: Tuesday, 6 November 2012, 13:45

CANCER – Clinical Outcomes Studies

PCN1

USE OF THE 5-HT3-RA ANTIEMETICS IN THE PREVENTION AND TREATMENT OF RADIATION INDUCED NAUSEA AND VOMITING

 

Knoth RL1, Faria C1, Chang E2, Broder M2
1Eisai, Inc., Woodcliff Lake, NJ, USA, 2Partnership for Health Analytic Research, Beverly Hills, CA, USA

PCN2

DATA ANALYSES ON PREVALENCE AND TREATMENT OF ACUTE MYELOID LEUKAEMIA IN GERMANY

 

Tomeczkowski J1, Theidel U2, Mittendorf T2, Fleischmann J1, Tapprich C1
1Janssen-Cilag GmbH, Neuss, Germany, 2Herescon GmbH, Hannover, Germany

PCN3

QUALITY-ADJUSTED SURVIVAL IN PATIENTS WITH WILD-TYPE (WT) KRAS METASTATIC COLORECTAL CANCER (MCRC) RECEIVING FIRST-LINE THERAPY WITH PANITUMUMAB PLUS FOLFOX VERSUS FOLFOX ALONE

 

Wang J1, Zhao Z2, Barber B2, Zhang J1, Sherrill B1, Braun S3, Sidhu R2, Gallagher M2, Douillard JY4
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Amgen Inc., Thousand Oaks, CA, USA, 3Amgen (Europe) GmbH, Zug, Switzerland, 4ICO R. Gauducheau, ST HERBLAIN , France

PCN4

DECISION-ANALYTIC MODEL FOR THE FIRST-LINE THERAPY OF CHRONIC MYELOID LEUKEMIA

 

Rochau U1, Sroczynski G2, Wolf D3, Schmidt S4, Conrads-Frank A2, Jahn B2, Saverno KR5, Brixner D6, Gastl G7, Radich J8, Siebert U9
1UMIT; Oncotyrol - Center for Personalized Cancer Medicine, Hall i.T.;Innsbruck, Tyrol, Austria, 2UMIT - University for Health Sciences, Medical Informatics and Technology; Oncotyrol - Center for Personalized Cancer Medicine, Hall i.T.;Innsbruck, Tyrol, Austria, 3University of Bonn, Medical University Innsbruck, Bonn/Innsbruck, Austria, 4Internal Medicine V, Hematology and Oncology, Medical University, Innsbruck, Austria, 5UMIT- Univ. for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria; Univ. of Utah, Salt Lake City, USA, Hall i.T.;Innsbruck, Tyrol, Austria, 6University of Utah, College of Pharmacy, Salt Lake City, UT, USA, 7Medical University Innsbruck, Innsbruck, Austria, 8Fred Hutchinson Cancer Center, Seattle, WA, USA, 9UMIT/ Oncotyrol/ Harvard University, Hall i.T.;Innsbruck, Tyrol, Austria

PCN5

CABAZITAXEL PLUS CORTICOSTEROIDS IN COMPARISON TO CORTICOSTEROIDS ALONE FOR THE TREATMENT OF METASTATIC HORMONE REFRACTORY / CASTRATION-RESISTANT PROSTATE CANCER (MHRPC)

 

Schinzel S1, Herbold M1, Bramlage P2
1Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany, 2Institut für Pharmakologie und präventive Medizin, Mahlow, Germany

PCN6

THE EVALUATION OF THE USE AND EFFECTIVENESS OF BEVACIZUMAB FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA IN DAILY PRACTICE

 

de Groot S1, Redekop W1, Oosting S2, Oosterwijk E3, Kiemeney L3, Uyl-de Groot C1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2University Medical Centre Groningen, Groningen, The Netherlands, 3Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

PCN7

A SYSTEMATIC REVIEW OF THE HETEROGENEITY OF TREATMENT EFFECT IN OVARIAN CANCER (OC)—ARE THERE IMPLICATIONS FOR OUTCOMES RESEARCH?

 

Chawla A1, Nellesen D1, Yee K1, Brown J2, Boye ME3
1Analysis Group, Inc., Menlo Park, CA, USA, 2Eli Lilly and Company, Windlesham, Surrey, UK, 3Eli Lilly and Company, Indianapolis, IN, USA

PCN8

AXITINIB (AXI) AND BEST SUPPORTIVE CARE (BSC) IN THE TREATMENT OF SUNITINIB-REFRACTORY PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RESULTS OF A SIMULATED TREATMENT COMPARISON (STC) ANALYSES

 

Proskorovsky I1, Benedict A2, Larkin JMG3, Sandin R4, Chen C5
1United BioSource Corporation, Dorval, QC, Canada, 2United BioSource Corporation, Budapest, Hungary, 3Royal Marsden Hospital, London, UK, 4Pfizer Oncology, Sollentuna, Stockholm, Sweden, 5Pfizer Global Pharmaceuticals, New York, NY, USA

PCN9

MODELING LIFETIME EFFECTIVENESS OF DENOSUMAB VERSUS PLACEBO IN MEN WITH CASTRATION RESISTANT PROSTATE CANCER (CRPC) AT HIGH RISK OF DEVELOPING BONE METASTASIS (BM)

 

Lothgren M1, Hechmati G1, Jacobs I2, Qian Y2, Arellano J2
1Amgen (Europe) GmbH, Zug, Switzerland, 2Amgen Inc., Thousand Oaks, CA, USA

PCN10

EXAMINING THE USE OF RESCUE ANTIEMETIC MEDICATION FOR CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN A COMMERCIAL POPULATION

 

Knoth RL1, Faria C1, Chang E2, Broder M2
1Eisai, Inc., Woodcliff Lake, NJ, USA, 2Partnership for Health Analytic Research, Beverly Hills, CA, USA

PCN11

THE IMPACT OF TREATMENT PERSISTENCE WITH LENALIDOMIDE (LEN) FOR THE TREATMENT OF MULTIPLE MYELOMA (MM) ON DISEASE CONTROL

 

Henk H1, Kaura S2, Khan Z2, Teitelbaum A3
1OptumInsight, Eden Prairie, MN, USA, 2Celgene Corporation, Summit, NJ, USA, 3OptumInsight, Life Sciences, San Diego, CA, USA

PCN13

ANALYSIS OF THE IMPACT OF PROPHYLACTIC VACCINATION AGAINST HUMAN PAPILLOMAVIRUS INFECTION USING A DYNAMIC-MODELLING APPROACH

 

Westra T1, Nijman H1, Wilschut J2, Daemen T1, Postma M3
1University Medical Center Groningen, Groningen, The Netherlands, 2University Medical Center Groningen, Groningen, Groningen, The Netherlands, 3University of Groningen, Groningen, Groningen, The Netherlands

PCN14

EVALUATION OF THE EFFICACY AND SIDE EFFECTS OF DACARBAZINE IN COMPARISON TO TEMOZOLOMIDE THERAPIES IN TREATMENT OF MALIGNANT MELANOMA. A META-ANALYSIS

 

Teimouri F1, Nikfar S2, Abdollahi M1
1Tehran University of Medical Sciences, Tehran, Iran, 2Tehran University of Medical Sciences, Tehran, Tehran, Iran

PCN15

CLINICAL AND COST-EFFECTIVENESS OF PROTON BEAM RADIOTHERAPY FOR EYE CANCER: A SYSTEMATIC REVIEW

 

Wlodarczyk A, Jaworska E, Budasz-Swiderska M
Agency for Health Technology Assessment In Poland (AHTAPol), Warsaw, Poland

PCN16

CLINICAL EFFECTIVENESS ANALYSIS OF SUNITINIB FOR THE TREATMENT OF PANCREATIC NEUROENDOCRINE TUMORS

 

Walczak J1, Jarosz J1, Lipińska M1, Prząda-Machno P2, Kroc J2
1Arcana Institute, Cracow, Poland, 2Pfizer Poland, Warsaw, Poland

PCN17

INDIRECT COMPARISON OF THE EFFICACY OF ERLOTINIB VERSUS PEMETREXED PLUS CISPLATIN AS FIRST LINE TREATMENT IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATING MUTATIONS

 

Pereira C1, Sanches M2, Loff JF3
1Roche Farmacêutica Quimica, Lda., Amadora, Portugal, 2Roche Farmacêutica Química, Lda., Amadora, Portugal, 3phiStat, Lisbon, Portugal

PCN19

MEDICAL MANAGEMENT OF METASTATIC RENAL CELL CARCINOMA, RETROSPECTIVE ANALYSIS OF REAL WORLD DATA SETTINGS

 

Kovacs E1, Nagy B2, Bidlo J3
1Healthware Consulting Ltd., Budapest, Hungary, 2Healthware Ltd, Budapest, Hungary, 3National Health Insurance Fund Administration, Budapest, Hungary

PCN20

INHALED CORTICOSTEROID USE AND RISKS OF LUNG CANCER AND LARYNGEAL CANCER

 

Hyun MK1, Lee CH2, Jang EJ1, Lee NR1, Kim K3, Yim JJ2
1National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea, 2Seoul National University College of Medicine, Seoul, South Korea, 3National Strategic Coordinating Center for Clinical Research, Seoul, South Korea

PCN21

WITHDRAWN

 

 

PCN22

IMMUNOTHERAPY WITH SIPULEUCEL-T (APC8015) IN PATIENTS WITH METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER (MCRPC): A SYSTEMATIC REVIEW AND META-ANALYSIS

 

Botrel TEA1, Clark OAC1, Pompeo ACL2, Bretas FFH2, Sadi MV2, Ferreira U2, Reis RBDR2
1Evidencias, Campinas, SP, Brazil, 2CoBEU - Comitê Brasileiro de Estudos em Uro-Oncologia, Campinas, SP, Brazil

PCN23

CANCER RELATED BISPHOSPHONATE THERAPY IN DIFFERENT TREATMENT FACILITIES

 

Haas G1, Kostev K2
1IMS Health, Frankfurt/Main, Germany, 2IMS Health, Frankfurt am Main, Germany

PCN24

TREATMENT AND RESPONSE PATTERNS IN CHRONIC MYELOID LEUKEMIA: EVIDENCE FROM A RETROSPECTIVE STUDY IN CANADA, AUSTRALIA, AND SOUTH KOREA

 

Mitra D1, Whiteley J2, Iyer S2, Candrilli S3, Kaye JA4
1RTI International, Research Triangle Park, NC, USA, 2Pfizer, New York, NY, USA, 3RTI Health Solutions, Research Triangle Park, NC, USA, 4RTI Health Solutions, Waltham, MA, USA

PCN25

A POPULATION-BASED PREDICTION OF BREAST CANCER IN RUSSIAN FEDERATION: ANALYSIS HER2-STATUS GROUPS FOR TARGET TREATMENT

 

Ryazhenov VV1, Gorokhova SG1, Frank G2, Zavalishina L2
1I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 2P.A. Herzen Research Oncology Institute of Moscow, Moscow, Russia

PCN26

GEOGRAPHIC VARIATION ASSOCIATED WITH COLORECTAL CANCER PREVALENCE IN THE UNITED STATES

 

Xie L1, Baser O2, Huang A3, Li L3, Fritschel EK3, Wang L3
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 3STATinMED Research, Dallas, TX, USA

PCN27

ANALYSIS OF PREVALENCE AND TREATMENT OF MULTIPLE MYELOMA IN GERMAN STATUTORY SICK FUNDS CLAIM DATA

 

Tomeczkowski J1, Wirth D1, Tapprich C1, Knauf W2
1Janssen-Cilag GmbH, Neuss, Germany, 2Oncology Group Practice, Frankfurt, Hessen, Germany

PCN28

STATIN USE AND RISK OF BREAST CANCER: A META-ANALYSIS OF 24 OBSERVATIONAL STUDIES

 

Undela K1, Srikanth V2
1National Institute of Pharmaceutical Education and Research, mohali, IN, India, 2National Institute of Pharmaceutical Education and Research, Mohali, IN, India

PCN29

INITIAL TREATMENT AND SURVIVAL AMONG ELDERLY PATIENTS WITH ADVANCED BREAST CANCER BY ESTROGEN RECEPTOR AND PROGESTERONE RECEPTOR STATUS: AN ANALYSIS OF THE UNITED STATES NATIONAL REGISTRY DATA 2000-2009

 

Lang K1, Huang H1, Namjoshi M2, Federico V1, Menzin J1
1Boston Health Economics, Inc., Waltham, MA, USA, 2Novartis Oncology US, East Hanover, NJ, USA

PCN30

TREATMENT PATTERNS AND OUTCOMES OF BREAST CANCER PATIENTS IN A PATIENT-CENTERED RETROSPECTIVE RESEARCH REGISTRY

 

Saokaew S1, Cai B1, Kuo KL2, Bauer H2, Albright F2, Brixner D2, Stenehjem D1
1University of Utah, Salt Lake City, UT, USA, 2University of Utah, College of Pharmacy, Salt Lake City, UT, USA

PCN31

TREATMENTS PATTERN AND OUTCOMES OF OVARIAN CANCER PATIENTS IN A PATIENT-CENTERED RETROSPECTIVE RESEARCH REGISTRY

 

Cai B1, Saokaew S2, Stenehjem D1, Kuo KL3, Bauer H3, Albright F3, Brixner D3
1University of Utah, Salt Lake City, UT, USA, 2University of Phayao, Phayao, Thailand, 3University of Utah, College of Pharmacy, Salt Lake City, UT, USA

PCN32

TREATMENT PATTERNS AND OUTCOMES OF MELANOMA PATIENTS IN A PATIENT-CENTERED RETROSPECTIVE RESEARCH REGISTRY

 

Kuo KL1, Saokaew S2, Cai B2, Bauer H1, Albright F1, Brixner D1, Stenehjem D2
1University of Utah, College of Pharmacy, Salt Lake City, UT, USA, 2University of Utah, Salt Lake City, UT, USA

PCN33

PROGRESSION-FREE SURVIVAL AS A SURROGATE FOR OVERALL SURVIVAL IN METASTATIC BREAST CANCER

 

Beauchemin C1, Cooper D2, Lapierre ME1, Yelle L3, Lachaine J1
1University of Montreal, Montreal, QC, Canada, 2Institut National d'Excellence en Sante et en Services Sociaux (INESSS), Quebec, QC, Canada, 3Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada

PCN34

RELATIONSHIP BETWEEN PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA

 

Beauchemin C1, Johnston J2, Lapierre ME1, Aissa F3, Lachaine J1
1University of Montreal, Montreal, QC, Canada, 2Manitoba Institute of Cell Biology
, Winnipeg, MB, Canada, 3Lundbeck Canada Inc., Montreal, QC, Canada

PCN35

SURVIVAL ESTIMATES OF SIX MAJOR ADVANCED AND METASTATIC SOLID TUMORS IN EUROPE: A CANCER REGISTRY AND LITERATURE REVIEW

 

Moulard O1, Mehta J2, Rose M3, Olivares R3, Hamed A2
1Sanofi, Chilly-Mazarin , France, France, 2Sanofi, Cambridge, MA, USA, 3Sanofi, Chilly-Mazarin, France, France

CANCER – Cost Studies

PCN36

VINORELBINE IN PATIENTS WITH NON-SMALL LUNG CANCER: BUDGET IMPACT ANALYSIS

 

Vitezic D1, Hadzic-Kostrencic C2, Petkovic M1, Dobrila-Dintinjana R1, Vitezica P2, Mrsic Pelcic J3
1University of Rijeka Medical School and University Hospital Centre Rijeka, Rijeka, Croatia, 2Pliva Croatia Ltd., Zagreb, Croatia, 3University of Rijeka, Rijeka, Croatia

PCN37

A PHARMACOECONOMIC ANALYSIS OF THE IMPLEMENTATION OF GEFITINIB IN THE TREATMENT OF METASTASIZED NON-SMALL CELL LUNG CANCER (NSCLC) WITH PROVEN EGFR-TK MUTATIONS

 

Culig J, Leppée M, Skaron-Jakobovic N
Andrija Stampar Institute of Public Health, Zagreb, Croatia

PCN38

IMPACT OF BIOMARKER TESTING ON CLINICAL AND ECONOMIC OUTCOMES IN ADVANCED CANCER TREATMENT

 

Sorensen S1, Pan F1, Knopf KB2
1United BioSource Corporation, Bethesda, MD, USA, 2Pacific Hematology Oncology Associates, San Francisco, CA, USA

PCN39

POTENTIAL TIME AND COST SAVINGS WITH HERCEPTIN (TRASTUZUMAB) SUBCUTANEOUS (SC) INJECTION VERSUS HERCEPTIN INTRAVENOUS (IV) INFUSION: RESULTS FROM THREE DIFFERENT ENGLISH PATIENT SETTINGS

 

Samanta K, Moore L, Jones G, Evason J, Owen G
Roche Products Limited, Welwyn Garden City, UK

PCN40

YEAR TO YEAR BUDGET IMPACT ANALYSIS OF BIOLOGICAL THERAPIES FOR FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN

 

Martínez-Amores B1, Mezquita L2, Ibáñez de Cáceres I3, Ayuso Á2, Peña JM4, Perona R3, Grande E5, Belda-Iniesta C6
1Hospital Rey Juan Carlos, Madrid, Spain, 2Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain, 3IdiPAZ, Madrid, Spain, 4School of Informatics.
UPM, Madrid, Spain, 5Hospital Universitario Ramón y Cajal, Madrid, Spain, 6Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Madrid, Spain

PCN41

COST-EFFECTIVENESS ANALYSIS OF IMMUNONUTRITION FOR UPPER GASTROINTESTINAL CANCER PATIENTS UNDERGOING SURGERY IN BRITISH HOSPITALS

 

Chevrou-Severac H1, Eijgelshoven I2, Weijers L2
1Nestle Health Science, VEVEY, Switzerland, 2MAPI Consultancy, Houten, The Netherlands

PCN42

COST OF PROSTATE IMAGE-GUIDED RADIATION THERAPY: RESULTS FROM A RANDOMIZED TRIAL

 

Perrier L1, Morelle M1, Pommier P1, Lagrange JL2, Laplanche A3, De Crevoisier R4
1Leon Berard Cancer Centre, Lyon, France, 2University Hospital Henri Mondor, Créteil, France, 3Insitut Gustave Roussy, Villejuif, France, 4Eugene Marquis Cancer Centre, Rennes, France

PCN43

COST ASSESSMENT OF COMPANION DIAGNOSTICS IN BREAST CANCER

 

Thakur D, Jha R, Kaur S, Sharan N, Kaur H
HERON Health Pvt. Ltd., Chandigarh, Chandigarh, India

PCN44

COST COMPARISON ANALYSIS OF ANTIBODY THERAPIES IN THE METASTATIC COLORECTAL CARCINOMA

 

Mercsanits D, Said M, Dragosits A, Walter E
Institute for Pharmaeconomic Research, Vienna, Austria

PCN45

ECONOMIC EVALUATION OF USING BRANDED TAXOTERE® VERSUS GENERIC DOCETAXEL: BASED ON DECISION TREE MODEL

 

Al Ameri MN, Tucker A, Johnston A
William Harvey Research Institute, Queen Mary University of London, London, UK

PCN46

COST-EFFICACY ANALYSIS OF LICENSED DRUGS FOR THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER POST DOCETAXEL BASED ON HOSPITAL DRUG EVALUATION METHODOLOGY IN SPAIN

 

Ostalé S, Ruiz P
Janssen, Madrid, Madrid, Spain

PCN47

COST-OF-ILLNESS OF COMMON CANCER TYPES - RESULTS OF A HEALTH INSURANCE CLAIMS DATA ANALYSIS

 

Damm O, Leppert F, Greiner W
School of Public Health, Bielefeld University, Bielefeld, Germany

PCN48

THE COST OF TREATING PENILE CANCER IN ENGLISH HOSPITALS: PRELIMINARY RESULTS USING THE HOSPITAL EPISODES STATISTICS (HES) DATABASE

 

Tempest MJ1, Keeping ST2, Carroll SM3, Thurston S1
1Pharmerit Ltd, York, UK, 2Sanofi Pasteur MSD, Maidenhead, Berkshire, UK, 3Sanofi Pasteur MSD, Maidenhead, UK

PCN49

ECONOMIC BURDEN OF MELANOMA IN RUSSIA

 

Ignateva V1, Derkach EV2, Omelyanovsky V1, Avxentyeva M1
1Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National Research Medical University, Moscow, Russia, 2Russian State Medical University, Moscow, Russia

PCN50

TREATMENT PATTERNS, HEALTH CARE UTILIZATION, AND COSTS OF OVARIAN CANCER IN CENTRAL AND EASTERN EUROPE USING A DELPHI PANEL BASED ON A RETROSPECTIVE CHART REVIEW

 

Kim K1, Hernlund E1, Justo N1, Hernadi Z2, Pete I3, Révész J4, Szánthó A5, Bodnar L6, Madry R7, Timorek-Lemieszczuk A8, Bozanovic T9, Vasovic S10, Tomasevic Z10, Zivaljevic M11, Pazin V12, Minárik T13, Garanová H14, Heľpianska L15
1OptumInsight, Stockholm, Sweden, 2Medical University of Debrecen, Clinic of Gynaecology, Debrecen, Hungary, 3National Oncological Institute, Budapest, Hungary, 4Department of Gynecology in County Hospital of BAZ, Miskolc , Hungary, 5Semmelweis University Budapest, Clinic of Gynecology, Budapest, Hungary, 6Military Institute of Medicine, Warsaw, Poland, 7Poznań University of Medical Sciences, Poznań, Poland, 8Warsaw Medical University, Warsaw, Poland, 9Medical Faculty, University of Belgrade, Belgrade, Serbia and Montenegro, 10Institute for oncology and radiology of Serbia, Belgrade, Serbia and Montenegro, 11Institute for Oncology of Vojvodina, Sremska Kamenica, Serbia and Montenegro, 12Gynecology and Obstetrics “Narodni Front”, Belgrade, Serbia and Montenegro, 13Národný onkologicky ústav, Bratislava, Slovak Republic, 14Východoslovenský onkologický ústav, Košice, Slovak Republic, 15Onkologický ústav sv. Alžbety, Bratislava, Slovak Republic

PCN51

COMPREHENSIVE INVESTIGATION OF ADVERSE EVENT (AE)-RELATED COSTS IN PATIENTS WITH METASTATIC BREAST CANCER (MBC) TREATED WITH FIRST- AND SECOND-LINE CHEMOTHERAPIES

 

Hurvitz SA1, Guerin A2, Brammer M3, Guardino E3, Zhou ZY4, Kaminsky MS4, Wu EQ4, Lalla D3
1UCLA, Santa Monica, CA, USA, 2Analysis Group, Ltee., Montreal, QC, Canada, 3Genentech, South San Francisco, CA, USA, 4Analysis Group, Inc., Boston, MA, USA

PCN52

ENGLISH HOSPITAL COSTS FOR ANAL CANCER: PRELIMINARY RESULTS FROM AN INVESTIGATION USING HOSPITAL EPISODES STATISTICS (HES)

 

Tempest MJ1, Keeping ST2, Thurston S1, Carroll SM3
1Pharmerit Ltd, York, UK, 2Sanofi Pasteur MSD, Maidenhead, Berkshire, UK, 3Sanofi Pasteur MSD, Maidenhead, UK

PCN53

REAL WORLD MANAGEMENT AND COSTS IN METASTATIC MALIGNANT MELANOMA (MM) PATIENTS: A PILOT STUDY BASED ON AN INSTITUTIONAL PATIENT REGISTRY

 

Strens D1, Specenier P2, Peeters M3
1Realidad, GRIMBERGEN, Belgium, 2University Hospital Antwerp, Edegem, Belgium, 3University Hospital Antwerp, Edegem, Edegem, Belgium

PCN54

ECONOMIC BURDEN ASSOCIATED WITH PANCREATIC CANCER IN EUROPE

 

Kaushal M, Ahuja A, Sharan N, Sharma D, Arora A
HERON Health Pvt. Ltd., Chandigarh, India

PCN55

THE COST OF RARE DISEASES: THE EXAMPLE OF CHRONIC LYMPHOCYTIC LEUKEMIA

 

Blankart CR1, Koch T1, Linder R2, Verheyen F2, Schreyögg J1, Stargardt T1
1University of Hamburg, Hamburg, Germany, 2Scientific Institute of TK for Benefit and Efficiency in Health Care, Hamburg, Germany

PCN56

PRELIMINARY RESULTS FROM A STUDY OF HOSPITAL COSTS DUE TO TREATMENT OF HEAD AND NECK CANCERS IN ENGLAND

 

Tempest MJ1, Thurston S1, Carroll SM2, Keeping ST3
1Pharmerit Ltd, York, UK, 2Sanofi Pasteur MSD, Maidenhead, UK, 3Sanofi Pasteur MSD, Maidenhead, Berkshire, UK

PCN57

ECONOMIC BURDEN OF PROSTATE CANCER IN RUSSIA

 

Ignateva V1, Derkach EV2, Omelyanovsky V1, Avxentyeva M1, Sveshnikova ND3, Grabareva D4
1Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National Research Medical University, Moscow, Russia, 2Russian State Medical University, Moscow, Russia, 3Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Moscow, Russia, 4Janssen, the pharmaceutical division of Johnson & Johnson LLC, Moscow, Russia

PCN58

HEALTH ECONOMIC IMPACT OF COLORECTAL CANCER

 

Kriza C, Wahlster P, Niederländer C, Schaller S, Kolominsky-Rabas P
University of Erlangen-Nuremberg, Erlangen, Germany

PCN59

PATTERNS OF CLINICAL MANAGEMENT AND RESOURCE UTILIZATION FOR POSTMENOPAUSAL HORMONE RECEPTOR–POSITIVE HER2-NEGATIVE (HR+ HER2) ADVANCED BREAST CANCER (ABC) IN EUROPE

 

Andre F1, Marinsek N2, Ricci JF3, Etchberger J2, Degun R2, Benelli G4, Saletan S5, Jerusalem G6
1Institut Gustave Roussy, Villejuif, France, 2Navigant Consulting, Inc, London, UK, 3Wellmera AG, Basel, Switzerland, 4Novartis Farma S.p.A, Saronno, VA, Italy, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 6Centre Hospitalier Universitaire du Sart Tilman Liège, Liege, Belgium

PCN60

THE COST STUDY OF TREATING MCRC WITH BEVACIZUMAB PLUS CHEMOTHERAPY IN THE REAL CLINICAL PRACTICE IN THE CZECH REPUBLIC

 

Hradecka I1, Rihova B1, Horova R2, Demlova R1
1Masaryk University, Brno, Czech Republic, 2Masaryk Memorial Cancer Institute, Brno, Czech Republic

PCN61

MELODY BRAZIL – RESOURCE USE AND ASSOCIATED COSTS WITH METASTATIC MELANOMA IN BRAZILIAN HEALTH CARE SYSTEM

 

Stefani SD1, Nita ME2, Nunes J3, Campos E4, Schmerling RA5, Barrios C6, Dzik C7, Alves JS2, Johnston K8, Donato BMK9
1Hospital Mãe de Deus, Porto Alegre, RS, Brazil, 2Bristol-Myers Squibb S/A, São Paulo, SP, Brazil, 3Hospital Cancer Barretos, Barretos, Brazil, 4Univille (Universidade da Região de Joinville), Joinville, Brazil, 5Hospital São José – Beneficência Portuguesa de São Paulo, São Paulo , Brazil, 6School of Medicine, Pontifical University Catholic RS, Porto Alegre, Brazil, 7Hospital Sirio Libanes, Sao Paulo, Brazil, 8Oxford Outcomes, Vancouver, BC, Canada, 9Bristol-Myers Squibb Company, Wallingford, CT, USA

PCN62

COST IMPACT MODELING OF TARGETED MOLECULAR PROFILING IN THE TREATMENT OF COLON CANCER

 

Hertz D1, Garfield S1, Wright B2, Spalding T2, Basu G2, Arguello D2, Walker I2, Paul L2, Brisbin L2, Russell K2, Cunniffe A2, Wright A2
1GfK Bridgehead, Wayland, MA, USA, 2Caris Life Sciences, Irving, TX, USA

PCN63

THE RELATIVE VALUE OF DASATINIB VERSUS IMATINIB AS FIRST-LINE TREATMENT FOR CHRONIC MYELOID LEUKEMIA

 

Betegon L1, Gilloteau I2, Martin P3, Woolmore A4, Oyagüez I5
1Bristol-Myers Squibb, Madrid, Spain, 2Bristol-Myers Squibb Company, Rueil Malmaison, France, 3Bristol-Myers Squibb Iberia, Madrid, Spain, 4Monitor Group Paris, Paris, France, 5Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain

PCN64

COST-CONSEQUENCE ANALYSIS (CCA) OF THE TREATMENT OF GROWING SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) SECONDARY TO TUBEROUS SCLEROSIS COMPLEX (TSC) IN BRAZIL

 

Valentim J1, Stillman IO2, Whalen JD2
1Novartis Pharmaceuticals, Sao Paulo, Brazil, 2United BioSource Corporation, Lexington, MA, USA

PCN65

COST-EFFECTIVENESS ANALYSIS OF INTRODUCING HPV VACCINES IN COLOMBIAN WOMEN

 

De la Hoz-Restrepo F1, Castañeda-Orjuela CA1, Carrasquilla M2, Alvis N3
1Universidad Nacional de Colombia, Bogota, NA, Colombia, 2Universidad de Cartagena, Cartagena de Indias, Cartagena de Ind, Colombia, 3Universidad de Cartagena, Cartagena, Bolívar, Colombia

PCN66

COST-EFFECTIVENESS OF DENOSUMAB VERSUS ZOLEDRONIC ACID FOR SKELETAL-RELATED EVENT (SRE) REDUCTION IN BONE-METASTATIC PROSTATE CANCER (MPC) IN THE UK

 

Botteman MF1, Carter JA1, Fishman P2, Chandiwana D3, Bains M3, Snedecor SJ1
1Pharmerit International, Bethesda, MD, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3Novartis Pharmaceuticals UK Limited, Camberley, Surrey, UK

PCN67

ECONOMIC EVALUATION OF MONO AND SEQUENTIAL HORMONE THERAPIES FOR ER+ WOMEN WITH EARLY BREAST CANCER IN CANADA

 

Djalalov S1, Beca J1, Li B2, Krahn M3, Hoch J4
1St. Michael's Hospital, Toronto, ON, Canada, 2Ontario Ministry of Health and long term care, Toronto, ON, Canada, 3Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada, 4Cancer Care Ontario, Toronto, ON, Canada

PCN68

PHARMACOECONOMIC EVALUATION OF RITUXIMAB AS MAINTENANCE TREATMENT FOR RELAPSED FOLLICULAR LYMPHOMA: RESULTS OF A REAL-WORLD POPULATION BASED STUDY

 

Blommestein H1, Issa D2, Pompen M3, Révil C4, Hoogendoorn M5, Joosten P5, Huijgens P6, Uyl-de Groot C7
1Erasmus University, Rotterdam, Zuid-Holland, The Netherlands, 2VU Medical Center, Amsterdam, The Netherlands, 3Roche, Woerden, Woerden, The Netherlands, 4F. Hoffmann-La Roche Ltd., Basel, Switzerland, 5Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands, 6VU University Medical Center, Amsterdam, Noord-Holland, The Netherlands, 7Erasmus University, Rotterdam, Zuid Holland, The Netherlands

PCN69

COST-EFFECTIVENESS ANALYSIS OF MAINTENANCE TREATMENT WITH RITUXIMAB (MABTHERA) FOR NON-HODGKINS LYMPHOMA PATIENTS IN GREECE, A LOCAL ADAPTATION

 

Demousis F, Athanasiadis A
Foundation for Economic and Industrial Research (IOBE), Athens, Greece

PCN70

THE COST EFFECTIVENESS OF DEGARELIX FOR THE TREATMENT OF PROSTATE CANCER IN THE UNITED KINGDOM

 

Lee D1, Gladwell D1, Nielsen SK2, Tate E3, Brereton NJ1
1BresMed, Sheffield, UK, 2Ferring International Center SA, St. Prex, Switzerland, 3Hayward Medical Communications, Newmarket, Suffolk, UK

PCN71

COST-EFFECTIVENESS ANALYSIS OF CETUXIMAB AND PANITUMUMAB AS FIRST-LINE THERAPIES FOR METASTATIC COLORECTAL CANCER IN SPAIN

 

Moreno V1, Martínez-Amores B2, Barriuso J1, Mezquita L3, Ibáñez de Cáceres I4, Ayuso Á3, Peña JM5, Perona R4, Grande E6, Belda-Iniesta C7
1University Hospital La Paz, Madrid, Spain, 2Hospital Rey Juan Carlos, Madrid, Spain, 3Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain, 4IdiPAZ, Madrid, Spain, 5School of Informatics.
UPM, Madrid, Spain, 6Hospital Universitario Ramón y Cajal, Madrid, Spain, 7Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Madrid, Spain

PCN72

MODELING THE SURVIVAL LOSS IN PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) SWITCHED FROM IMATINIB MESYLATE TO A GENERIC COPY

 

Botteman M1, Magestro M2, Alwan AF3
1Pharmerit International, Bethesda, MD, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3The National Center of Hematology, Baghdad, Iraq

PCN73

ECONOMIC ANALYSIS OF THE USE OF CRIZOTINIB, A TYROSINE KINASE ALK INHIBITOR, IN THE TREATMENT OF ALK POSITIVE NON-SMALL CELL LUNG CANCER IN THE MEXICAN SETTING

 

Gay-Molina JG1, Sánchez-Kobashi R2, Muciño-Ortega E3, Gutiérrez-Colín CI3, Galindo-Suárez RM3
1Tecnología e Informática para la Salud, S.A. de C.V., Mexico City, Distrito Federal, Mexico, 2Tecnología e Informática para la Salud, S.A. de C.V., Mexico City, Mexico, 3Pfizer S.A. de C.V., Mexico City, Mexico

PCN74

COST EFFECTIVENESS OF CYCLOPHOSPHAMIDE IN THE ADJUVANT TREATMENT OF BREAST CANCER IN EUROPE: A MULTI-COUNTRY STUDY

 

Walter E, Mercsanits D
Institute for Pharmaeconomic Research, Vienna, Austria

PCN75

SURVIVAL AND COSTS IN METASTATIC RENAL CELL CARCINOMA: A COMPARISON OF MRCC TREATMENT PRE- AND POST TYROSINE KINASE INHIBITOR (TKI) INTRODUCTION USING RETROSPECTIVE REGISTRY DATA

 

Jönsson L1, Sandin R2, Lindgren P1, Kowalski J3, Wahlgren T2, Harmenberg U4, Sandström P4, Ljungberg B5, Jakobsson M2
1OptumInsight and Karolinska Institutet, Stockholm, Sweden, 2Pfizer AB, Sollentuna, Sweden, 3Karolinska University Hospital Huddinge and Karolinska Institutet Huddinge, Stockholm, Sweden, 4Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 5Umeå University, Umeå, Sweden

PCN76

COST-EFFECTIVENESS OF ERLOTINIB AS FIRST-LINE MAINTENANCE THERAPY FOR ADVANCED NON-SMALL-CELL LUNG CARCINOMA IN PATIENTS EGFR WT AND STABLE DISEASE AFTER FOUR CYCLES OF CHEMOTHERAPY

 

Cobo M1, De Castro J2, Isla D3, Oyagüez I4, Lozano V5, Castro-Gomez A6
1Hospital Regional Universitario Carlos Haya, Malaga, Spain, 2Hospital Universitario La Paz, Madrid, Spain, 3Hospital Clinico Lozano Blesa, Zaragoza, Spain, 4Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 5Pharmacoeconomics and Outcomes Research Iberia, Madrid, Spain, 6Roche, Madrid, Spain

PCN77

COST EFFECTIVENESS ANALYSIS IN THE VENETO REGION OF NAB-PACLITAXEL MONOTHERAPY II LINE VERSUS CONVENTIONAL PACLITAXEL IN PATIENTS WITH BREAST CANCER AND FOR WHOM ANTHRACYCLINES ARE NOT INDICATED

 

Maran PR1, Aiello A1, Magrì MR1, Alberti C1, Visentin E1, Venturini F2, Scroccaro G3
1UVEF Regional Drug Coordination Centre, Verona, Italy, Italy, 2Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy, 3Regione del Veneto, Venezia, Italy

PCN78

COST-EFFECTIVENESS OF PLERIXAFOR PLUS GCSF FOR MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH MYELOMA AND LYMPHOMA IN SPAIN

 

Duarte RF1, Pérez-Simón JA2, Martín G3, de la Rubia J4, Marín P5, Álvarez MA6, Espinós B7, Roset M7
1Institut Català D'Oncologia - Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain, 2Hospital Universitario Virgen del Rocío, Sevilla, Spain, 3Banc de Sang i Teixits, Barcelona, Spain, 4Hospital Universitario La Fe de Valencia, Valencia, Spain, 5Hospital Clínic, Barcelona, Spain, 6Hospital Reina Sofía, Córdoba, Spain, 7IMS Health, Barcelona, Spain

PCN79

PHARMACOECONOMIC EVALUATION OF ACUTE MYELOID LEUKEMIA AND MDS SYNDROMES (INTERMEDIATE AND HIGH RISK) TREATMENT WITH AZACITIDINE IN THE RUSSIAN FEDERATION

 

Kulikov A, Yagudina R, Misikova B
I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PCN80

MODELLING THE COST-EFFECTIVENESS OF IPILIMUMAB FOR PREVIOUSLY-TREATED, METASTATIC MELANOMA

 

Lee D1, Winn B1, Lebmeier M2, Batty A1
1BresMed, Sheffield, UK, 2Bristol-Myers Squibb Company, Uxbridge, Middlesex, UK

PCN81

COST EFFECTIVENESS OF PAZOPANIB IN SOFT TISSUE SARCOMA

 

Amdahl J1, Manson S2, Isbell R2, Chit AN3, Diaz JR4, Lewis L5, Delea TE6
1PAI, Brookline, MA, USA, 2GlaxoSmithKline, Uxbridge, UK, 3GlaxoSmithKline, Mississauga , ON, Canada, 4GlaxoSmithKline, London, London, UK, 5University of York, York, UK, 6Policy Analysis Inc. (PAI), Brookline, MA, USA

PCN82

COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS PLATINUM BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER EGFR ACTIVATING MUTATIONS

 

Garrido P1, López-Vivanco G2, Rosell R3, Espinós B4, Castro-Gomez A5
1Hospital Universitario Ramón y Cajal, Madrid, Spain, 2Hospital de Cruces, Barakaldo, Spain, 3Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 4IMS Health, Barcelona, Spain, 5Roche, Madrid, Spain

PCN83

COST EFFECTIVENESS ANALYSIS IN THE VENETO REGION OF CABAZITAXEL VERSUS MITOXANTRONE IN PATIENTS WITH METASTATIC HORMONE REFRACTORY PROSTATE CANCER, PREVIOUSLY TREATED WITH A DOCETAXEL CONTAINING REGIMEN

 

Maran PR1, Aiello A1, Magrì MR1, Alberti C1, Visentin E1, Venturini F2, Scroccaro G3
1UVEF Regional Drug Coordination Centre, Verona, Italy, Italy, 2Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy, 3Regione del Veneto, Venezia, Italy

PCN84

ABIRATERONE ACETATE VERSUS CABAZITAXEL IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: AN ECONOMIC EVALUATION IN THE GREEK HEALTH CARE SETTING

 

Efstathiou E1, Gyftaki R2, Kousoulakou H3, Paparouni K4, Ikonomou V4
1MD, PhD, Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece, 2MD, Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece, 3PRMA Consulting, Fleet, UK, 4Janssen Cilag Pharmaceutical SACI, Athens, Greece

PCN85

ECONOMIC ASSESSMENT OF THE ONCOTYPE DX BREAST CANCER ASSAY

 

Escalona S1, Callejo D2, Blasco JA1
1Lain Entralgo Agency, Madrid, Madrid, Spain, 2LA-SER (BAP LA-SER Outcomes), Oviedo, Asturias, Spain

PCN86

COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE FOR THE TREATMENT OF ADVANCED PROSTATE CANCER UNDER THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

 

Pereira ML1, Bahmdouni LSK1, Pepe C2, Teich V2
1Janssen Cilag Farmaceutica, São Paulo, Brazil, 2MedInsight, São Paulo, São Paulo, Brazil

PCN87

COST EFFECTIVENESS EVALUATION OF VEMURAFENIB, AN ORPHAN DRUG FOR BRAF MUTANT METASTATIC MELANOMA

 

Alva M1, Gay JG2, Sanchez Kobashi R3
1Roche Mexico, Mexico City, Mexico, 2T.I. Salud, Mexico, Mexico City, Mexico, 3T.I. Salud, Mexico City, Mexico City, Mexico

PCN88

COST-EFFECTIVENESS ANALYSIS PER LIFE-YEAR GAINED BASED ON PREDICTORS OF RESPONSE FOR FIRST LINE METASTASIC COLORECTAL CANCER THERAPY IN SPAIN

 

Belda-Iniesta C1, Moreno V2, Martínez-Amores B3, Barriuso J2, Mezquita L1, Ibáñez de Cáceres I4, Ayuso Á1, Peña JM5, Perona R4, Grande E6, Saz-Parkinson Z7, Amate JM7
1Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain, 2University Hospital La Paz, Madrid, Spain, 3Hospital Rey Juan Carlos, Madrid, Spain, 4IdiPAZ, Madrid, Spain, 5School of Informatics.
UPM, Madrid, Spain, 6Hospital Universitario Ramón y Cajal, Madrid, Spain, 7Instituto de Salud Carlos III, Madrid, Spain

PCN89

COST EFFECTIVENESS OF TREATMENT WITH NEW 6-MONTH LEUPRORELIN ACETATE FORMULATION IN PATIENTS WITH ADVANCED PROSTATE CANCER

 

Tundia NL1, Fuldeore M2, Gruca D3, Hass S2, Bacher P2, Bodhani A2
1University of Cincinnati, Cincinnati, OH, USA, 2Abbott Laboratories, Abbott Park, IL, USA, 3Abbott Laboratories, Ludwigshafen , Germany

PCN90

COST EFFECTIVENESS ANALYSIS OF BENDAMUSTINE AS FIRST LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE NETHERLANDS

 

Vandekerckhove S1, Holtzer-Goor K2, Van Den Steen D1, van Megen Y3, Huijgens P4, Lamotte M1, Uyl- de Groot C5
1IMS Health, Vilvoorde, Belgium, 2iMTA, Rotterdam, Zuid Holland, The Netherlands, 3Mundipharma Pharmaceuticals, HOEVELAKEN, The Netherlands, 4VU University Medical Center, Amsterdam, The Netherlands, 5Erasmus University, Rotterdam, The Netherlands

PCN91

THE COST-EFFECTIVENESS OF TRASTUZUMAB OVER THE PRODUCT LIFE CYCLE IN PORTUGAL: A DYNAMIC AND SOCIETAL PERSPECTIVE

 

Garrison L1, Babigumira JB2, Andrade S3
1University of Washington School of Pharmacy, Seattle, WA, USA, 2University of Washington, Seattle, WA, USA, 3Roche Farmacêutica Química, Lda., Amadora, Portugal

PCN92

COST-EFFECTIVENESS OF NILOTINIB VERSUS IMATINIB AS FIRST-LINE TREATMENT FOR NEWLY DIAGNOSED PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE (CML-CP) IN RUSSIAN FEDERATION

 

Yagudina R, Kulikov A, Komarov I
I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PCN93

TREATMENT OF WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS WITH SUNITINIB IN PATIENTS WITH DISEASE PROGRESSION: COST-UTILITY AND COST-EFFECTIVENESS ANALYSIS

 

Walczak J1, Garbacka M1, Zawieja J1, Prząda-Machno P2, Kroc J2
1Arcana Institute, Cracow, Poland, 2Pfizer Poland, Warsaw, Poland

PCN94

FEASIBILITY OF EFFICIENCY FRONTIER ANALYSIS (EFA) IN METASTATIC BREAST CANCER (MBC) TREATMENTS: A UK PERSPECTIVE

 

Burudpakdee C1, Bertwistle D2
1IMS Health, Alexandria , VA, USA, 2IMS Health, London, UK

PCN95

PHARMACOECONOMIC ANALYSIS OF DIRECT MEDICAL COSTS ASSOCIATED WITH THE TREATMENT OF ADVANCED ESOPHAGO-GASTRIC CANCER THERAPY WITH XELODA OR 5-FLUOROURACIL (5-FU) REGIMENS: IMPLICATIONS FOR HEALTHCARE UTILISATION IN AUSTRALIA

 

Tran G1, Hack S1, Kerr A1, Stokes L2, Gibbs P3, Price T4, Todd C1
1Roche Products Pty. Ltd., DEE WHY, NSW, Australia, 2Pretium Pty Ltd, Sydney, NSW, Australia, 3Royal Melbourne Hospital, Melbourne, Victoria, Australia, 4Queen Elizabeth Hospital, Woodville, South Australia, Australia

PCN96

COST MINIMIZATION ANALYSIS OF XELODA® VERSUS 5-FLUOROURACIL-BASED TREATMENT FOR GASTRIC CANCER PATIENTS IN HONG KONG

 

Zhou KR1, Cheng A2, Kwok TY1, Yao R2, Yip E2, Lee VW1
1The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, 2Princess Margaret Hospital, Kowloon, Kowloon, Hong Kong

PCN97

PHARMACOECONOMIC ANALYSIS OF THE PROSTATE CANCER THERAPY WITH GONADOTROPIN-RELEASING HORMONE ANALOGUES: LEUPRORELIN, GOSERELIN, TRIPTORELIN

 

Omelyanovsky V1, Avxentyeva M1, Ivakhnenko O1, Khailov P2, Krysanov I1, Maksimova L3
1Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National Research Medical University, Moscow, Russia, 2Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National Research Medical University, Moscow, Russia, 3Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian State Medical University, Moscow, Russia

PCN98

HEALTH OUTCOME GAINS AND COSTS OFFSET ASSOCIATED WITH EVEROLIMUS FOR THE TREATMENT OF HORMONE-RECEPTOR–POSITIVE (HR+) HER2-NEGATIVE (HER2) ADVANCED BREAST CANCER (ABC)

 

Taylor M1, Lewis L1, Vieira J2, Ricci JF3, Chandiwana D2, Saletan S4, Sahmoud T4
1York Health Economics Consortium, York, UK, 2Novartis Pharmaceuticals UK Limited, GB- Frimley/Camberley, Surrey, UK, 3Wellmera AG, Basel, Switzerland, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PCN99

COST-UTILITY OF GRANULOCYTE-COLONY STIMULATING FACTORS FOR PRIMARY PROPHYLAXIS OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA IN BREAST CANCER PATIENTS IN BELGIUM

 

Somers L1, Malfait M2, Danel A3
1OncoLogX bvba, Wuustwezel, Antwerp, Belgium, 2Amgen sa/nv, Brussels, Belgium, 3Amgen (Europe) GmbH, Zug, Switzerland

PCN100

COST UTILITY ANALYSIS OF BORTEZOMIB IN A BIOMARKER POSITIVE SUBGROUP OF RELAPSED AND REFRACTORY FOLICULAR LYMPHOMA

 

Vandekerckhove S1, Lamotte M1, Iannazzo S2, Chirita O3
1IMS Health, Vilvoorde, Belgium, 2IMS HEOR, Milan, Italy, 3Janssen-Cilag Ltd., Buckinghamshire , UK

PCN101

COST EFFECTIVENESS OF EVEROLIMUS FOR SECOND LINE TREATMENT OF METASTATIC RENAL CELL CANCER IN SERBIA

 

Mihajlović J1, Pechlivanoglou P1, Sabo A2, Tomić Z3, Postma MJ1
1University of Groningen, Groningen, The Netherlands, 2Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia and Montenegro, 3University of Novi Sad, Medical Faculty, Novi Sad, Serbia and Montenegro

PCN102

THE COST OF ABSENTEEISM AND SHORT-TERM DISABILITY ASSOCIATED WITH COLORECTAL CANCER: A CASE-CONTROL STUDY

 

Yaldo A1, Seal B2, Lage MJ3
1Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA, 2Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, USA, 3HealthMetrics Outcomes Research, Delray Beach, FL, USA

PCN103

HOW MUCH PRICE COMPONENT IS ACCOUNTED FOR IN STATE DRUGS PURCHASE DECISIONS IN UKRAINIAN ONCOLOGY?

 

Mandrik O1, Zalis'ka O1, Severens J2
1Danylo Halytsky Lviv National Medical University, Lviv, Ukraine, 2Erasmus University Rotterdam, Rotterdam, The Netherlands

PCN104

PROFILE OF PATIENTS AND HEALTH CARE COSTS ASSOCIATED WITH CANCER TREATMENT FROM A MEDICAL COOPERATIVE IN THE STATE OF SÃO PAULO, BRAZIL

 

Santos MCL, Maturana MS
Unimed São José do Rio Preto, São José do Rio Preto, São Paulo, Brazil

CANCER – Patient-Reported Outcomes & Patient Preference Studies

PCN105

IMPACT OF PHARMACY CHANNEL ON ABANDONMENT RATE OF ORAL ONCOLYTICS

 

Reyes C1, Stokes M2, Yu X3, Alas V3, Gatt E3, Boulanger L3
1Genentech, South San Francisco, CA, USA, 2United BioSource Corporation, Dorval, QC, Canada, 3United BioSource Corporation, Lexington, MA, USA

PCN106

PERSISTENCE IN PATIENTS WITH BREAST CANCER TREATED WITH TAMOXIFEN OR AROMATASE INHIBITORS: RESULTS OF A RETROSPECTIVE COHORT STUDY

 

Kostev K1, Haas G2, Hadji P3
1IMS Health, Frankfurt am Main, Germany, 2IMS Health, Frankfurt/Main, Germany, 3Universityhospital of Giessen and Marburg GmbH, Marburg, Hessen, Germany

PCN107

PERSISTENCE IN FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ROUTINE CARE IN GERMANY

 

Mergenthaler U1, Morawski E2, Wendschlag A1
1IMS Health, Frankfurt, Germany, 2Pfizer GmbH, Berlin, Germany

PCN108

QUALITY OF LIFE AND PATIENT PREFERENCES IN PLATINUM SENSITIVE OVARIAN CANCER

 

Kiss N1, Sidhu M1, Tongbram V2, Harris L3
1Oxford Outcomes, Morristown, NJ, USA, 2Oxford Outcomes Ltd., an ICON PLC Company, Morristown, NJ, USA, 3Eisai, Inc., Woodcliff Lake, NJ, USA

PCN109

QUALITY OF LIFE ASSESSMENT OF CHRONIC MYELOID LEUKEMIA PATIENTS IN AUSTRIA: CROSS-SECTIONAL PILOT STUDY USING THE EQ-5D

 

Rochau U1, Kallinger S2, Schmidt S3, Saverno KR4, Holzner B5, Schwarzer R2, Arvandi M2, Brixner D6, Gastl G3, Siebert U7
1UMIT; Oncotyrol - Center for Personalized Cancer Medicine, Hall i.T.;Innsbruck, Tyrol, Austria, 2UMIT - University for Health Sciences, Medical Informatics and Technology; Oncotyrol - Center for Personalized Cancer Medicine, Hall i.T.;Innsbruck, Tyrol, Austria, 3Medical University Innsbruck, Innsbruck, Austria, 4UMIT- Univ. for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria; Univ. of Utah, Salt Lake City, USA, Hall i.T.;Innsbruck, Tyrol, Austria, 5Innsbruck Medical University, Innsbruck, Tyrol, Austria, 6University of Utah, College of Pharmacy, Salt Lake City, UT, USA, 7UMIT/ Oncotyrol/ Harvard University, Hall i.T.;Innsbruck, Tyrol, Austria

PCN110

DIFFERENCES IN HEALTH-RELATED QUALITY OF LIFE BETWEEN CHILDREN TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) ON DANA FARBER CANCER INSTITUTE (DFCI) PROTOCOLS

 

Rae CS1, Horsman JR2, Furlong W2, Silverman LB3, Sallan SE3, Athale U1, Pullenayegum E1, Barr RD1
1McMaster University, Hamilton, ON, Canada, 2Health Utilities Inc., Dundas, ON, Canada, 3Harvard Medical School, Boston, MA, USA

PCN111

THE VALUE OF PERSONALIZING MEDICINE: MEDICAL ONCOLOGISTS' AND PATIENTS' PERSPECTIVES ON GENOMIC TESTING OF BREAST TUMOURS IN CHEMOTHERAPY TREATMENT DECISIONS

 

Marshall DA1, Bombard Y2, Rozmovits L3, Trudeau M4, Leighl N5, Deal K1
1McMaster University, Hamilton, ON, Canada, 2Memorial Sloan-Kettering Cancer Center, New York, NY, USA, 3Independent Qualitative Researcher, Toronto, ON, Canada, 4Sunnybrook Health Science Centre, Toronto, ON, Canada, 5Princess Margaret Hospital, Toronto, ON, Canada

PCN112

CHARACTERISTICS OF CANCER PATIENTS WHO SEEK CYTOSTATIC THERAPY IN KOREA: A PILOT STUDY

 

Kim EH, Park S, Lee JS, Choi HS, Kim KS, Kim S, Choi WC
Kyung Hee University, Seoul, South Korea

PCN113

ASSESSING HEALTH-RELATED QUALITY OF LIFE (HRQOL) FOR ADVANCED BASAL CELL CARCINOMA (ABCC) AND BASAL CELL CARCINOMA NEVUS SYNDROME (BCCNS): DEVELOPMENT OF THE FIRST DISEASE-SPECIFIC PATIENT-REPORTED OUTCOME (PRO) QUESTIONNAIRE

 

Mathias SD1, Chren MM2, Yim YM3, Colwell HH1, Reyes C3, Chen DM3, Fosko SW4
1Health Outcomes Solutions, Winter Park, FL, USA, 2San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA, 3Genentech, South San Francisco, CA, USA, 4St. Louis University School of Medicine, St. Louis, MO, USA

PCN114

DEFINING REGULATORY SUCCESS FOR PATIENT-REPORTED OUTCOMES (PROS) IN ONCOLOGY

 

Lenderking WR1, Pokrzywinski RF2, Currie B2, Wong B3, Park J4, Huang H5
1United BioSource Corporation, Lexington, MA, USA, 2United BioSource Corporation, Bethesda, MD, USA, 3University of Pennsylvania, Wayne, PA, USA, 4Millennium Pharmaceuticals, Inc., Boston, MA, USA, 5Millennium Pharmaceuticals, Inc., Cambridge, MA, USA

PCN115

QUALITY OF LIFE IN LUNG CANCER PATIENTS DURING ADJUVANT OR PALLIATIVE CHEMOTHERAPY

 

Wintner LM1, Zabernigg A2, Giesinger JM1, Sztankay M1, Gattringer K2, Gamper EM1, Holzner B1
1Innsbruck Medical University, Innsbruck, Tyrol, Austria, 2Kufstein County Hospital, Kufstein, Tyrol, Austria

PCN116

MAPPING FACT-P TO EQ-5D IN A LARGE CROSS-SECTIONAL STUDY OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER PATIENTS

 

Diels J1, Spencer M2, Hamberg P3, Wheatley Price P4, Dass RN5
1Janssen Pharmaceutica, Beerse, Belgium, 2Janssen-Cilag Limited, High Wycombe, Bucks, UK, 3Sint Franciscus Gasthuis, Rotterdam, The Netherlands, 4Janssen-Cilag Ltd., London, UK, 5Janssen-Cilag, London, UK

PCN117

QUALITY OF LIFE IN PATIENTS WITH MALIGNANT ASCITES AFTER TREATMENT WITH CATUMAXOMAB: A MULTICENTER PHASE II/III STUDY COMPARING PARACENTESIS PLUS CATUMAXOMAB WITH PARACENTESIS ALONE

 

Salek MS1, Deger M2, Wimberger P3, Gilet H4, Parsons SL5
1Cardiff University, Cardiff, UK, 2Fresenius Biotech GmbH, München , Germany, 3University of Duisburg-Essen, Essen, Germany, 4MAPI Consultancy, Lyon, France, 5Notthingham University Hospitals NHS Trust, Nottingham, UK

PCN118

IMPACT OF BONE METASTASES ON QUALITY OF LIFE IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AT HIGH RISK FOR DEVELOPING BONE METASTASES

 

Hechmati G1, Arellano J2, Haynes I3, Gunther O3, Worsfold A4, Rider A4
1Amgen (Europe) GmbH, Zug, Switzerland, 2Amgen Inc., Thousand Oaks, CA, USA, 3Amgen Ltd., Uxbridge, UK, 4Adelphi Real World, Macclesfield, Cheshire, UK

PCN119

PATIENT-REPORTED OUTCOMES (PROS) IN ANTINEOPLASTIC PRODUCT APPROVALS IN EUROPE AND IN THE USA

 

Patrick D1, Acquadro C2, Teschendorf B3, Emery MP2, Caron M2, Arnould B4
1University of Washington, Seatte, WA, USA, 2MAPI Research Trust, Lyon, France, 3Adelphi Values, Boston, MA, USA, 4MAPI Consultancy, Lyon, France

PCN120

QUALITY OF LIFE AMONG GERMAN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

 

Wolff JM1, Donatz V2, Klier J3, Erhardt W2, Dr. Dass RN4, Geiges G5
1Viersen General Hospital, Viersen, Germany, 2Janssen-Cilag, Neuss, Germany, 3Office-based Urologist, Köln, Germany, 4Janssen-Cilag Limited, High Wycombe, UK, UK, 5Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.V. (IQUO), Berlin, Germany

PCN121

DECITABINE REDUCES TRANSFUSION DEPENDENCE IN OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM A POST-HOC ANALYSIS OF A RANDOMISED PHASE III TRIAL

 

Dass RN1, Howes A1, Spencer M2, Xiu L3, Thomas XG4, Al-Dakkak I5
1Janssen-Cilag Limited, High Wycombe, UK, 2Janssen-Cilag Limited, High Wycombe, Bucks, UK, 3Janssen-Cilag Limited, Raritan, NJ, USA, 4Centre Hospitalier Lyon Sud, Pierre-Benite cedex, France, 5HERON Health, Luton, UK

PCN122

PILOT SURVEY TO ESTIMATE WILLINGNESS TO PAY (WTP) FOR PROPHYLACTIC GRANULOCYTE COLONY-STIMULATING FACTORS (G-CSFS) AMONG PREVIOUSLY TREATED BREAST CANCER PATIENTS

 

Johnson P1, Bancroft TJ1, Barron R2, Legg J2, Watson H2, Naeim A3, Watkins A1, Marshall D4
1OptumInsight, Eden Prairie, MN, USA, 2Amgen, Inc., Thousand Oaks, CA, USA, 3UCLA, Los Angeles, CA, USA, 4University of Calgary, Calgary, AB, Canada

PCN123

A CONJOINT ANALYSIS OF WILLINGNESS TO PAY TO AVOID METASTATIC BREAST CANCER SIDE EFFECTS

 

Lalla D1, Brammer M1, Carlton R2, Bramley T2, D'Souza AO3
1Genentech, South San Francisco, CA, USA, 2Xcenda, LLC, Palm Harbor, FL, USA, 3Xcenda, Cincinnati, OH, USA

PCN124

LOST PRODUCTIVITY IN POPULATION OF CANCER PATIENT'S CLOSE RELATIVES IN POLAND

 

Macioch T, Hermanowski TR
Medical University of Warsaw, Warsaw, Poland

PCN125

COST OF PRESENTEEISM DUE TO CANCER IN POLAND

 

Macioch T, Hermanowski TR
Medical University of Warsaw, Warsaw, Poland

CANCER – Health Care Use & Policy Studies

PCN126

CAN A POPULATION-BASED PATIENT REGISTRY IMPROVE THE FEASIBILITY OF OUTCOMES RESEARCH IN MULTIPLE MYELOMA?

 

Blommestein H1, Franken M2, Verelst S3, Gaultney JG4, Huijgens P5, Sonneveld P6, Redekop WK4, Uyl-de Groot C7
1Erasmus University, Rotterdam, Zuid-Holland, The Netherlands, 2Erasmus University, Rotterdam, The Netherlands, 3Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands, 4Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands, 5VU University Medical Center, Amsterdam, Noord-Holland, The Netherlands, 6Erasmus University Medical Center, Rotterdam, The Netherlands, 7Erasmus University, Rotterdam, Zuid Holland, The Netherlands

PCN127

POLICY MAKER, PLEASE CAREFULLY CONSIDER YOUR NEEDS: DOES OUTCOMES RESEARCH OF BORTEZOMIB FOR ADVANCED MULTIPLE MYELOMA REDUCE UNCERTAINTY?

 

Franken MG1, Gaultney JG1, Blommestein HM1, Huijgens PC2, Sonneveld P3, Redekop WK1, Uyl-de Groot CA1
1Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands, 2VU University Medical Center, Amsterdam, The Netherlands, 3Erasmus University Medical Center, Rotterdam, The Netherlands

PCN128

ESTIMATING THE VALUE OF COMPANION DIAGNOSTICS: ARE THE INCENTIVES RIGHT?

 

Nordyke RJ, Wang A, Zolfaghari S
PriceSpective LLC, El Segundo, CA, USA

PCN129

EMERGING MARKET ACCESS TRENDS: PRICING AND COVERAGE OF TARGETED CANCER THERAPIES IN RUSSIA (2011-2012)

 

Aggarwal S
Novel Health Strategies, Bethesda, MD, USA

PCN130

ROLE OF THE HEALTH CARE PAYMENT SYSTEM ON THE PATIENT ACCESS TO ORAL ANTICANCER DRUGS: A COMPARISON OF FRENCH AND NORTH AMERICAN SITUATIONS

 

Benjamin L1, Buthion V2, Vidal-Trécan G3
1University of Paris Descartes, School of Public Health (EHESP), GlaxoSmithKline, Marly le Roi, France, 2COACTIS EA 4161, University of Lyon, Lyon, France, 3Department of Public Health, Quality and Safety of care, Cochin Hospital, AP-HP, Paris, France

PCN131

PRICING THEORY AND REALITY: THE LINK BETWEEN OUTCOMES AND PRICE

 

Wild L, Forster L
InterPhase P&MA, London, London, UK

PCN132

DURATION OF GEFITINIB TREATMENT IN EGFR MUTATION POSITIVE NSCLC PATIENTS IN A UK SINGLE PAYEMENT ACCESS SCHEME (SPA)

 

Vioix H1, Franzen S2, Selby D1, Hauch O3, Emmas CE1
1AstraZeneca UK Ltd., Luton, UK, 2AstraZeneca R&D, Mölndal, Sweden, 3AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

PCN133

UTILISATION OF ANTINEOPLATIC AGENTS INVOLVED IN TREATMENT OF NSCLC IN SLOVAK REPUBLIC WITHIN 2008-2011

 

Bellova K1, Gatialova K2, Foltan V3, Majtás J4
1Comenius University in Bratislava, Bratislava, Slovak Republic, Slovak Republic, 2Pharmaceutical Faculty at Comenius University, Bratislava, Slovak Republic, 3Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic, 4Comenius University, Bratislava, Slovak Republic

PCN134

EXPENDITURES AND AVAILABILITY OF ORPHAN DRUGS IN THE CZECH REPUBLIC: SEVEN YEAR EXPERIENCE (2004 – 2010)

 

Klimes J1, Dolezal T1, Vocelka M1, Suchanková E1, Kruntoradova K2
1Institute of Health Economics and Technology Assessment, Prague, Czech Republic, 2Czech Technical University in Prague, Faculty of Biomedical Engineering, Kladno, Czech Republic

PCN135

THE ECONOMIC VALUE OF MEDICAL PROGRESS, THE CASE OF CANCER IN FRANCE (1990-2010)

 

Le Pen C
Dauphine University, Paris, France

PCN136

EXPENDITURES ON ORPHAN DRUGS IN CANADA, EUROPE (EU5 + BELGIUM, SWEDEN AND NETHERLANDS) AND AUSTRALIA IN 2009

 

Haddad P1, Hurry M2, Barbeau M1
1Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 2Novartis Pharmaceuticals Canada, Dorval, QC, Canada

PCN137

NICE TECHNOLOGY APPRAISALS AND THE UPTAKE OF BREAST CANCER DRUGS IN THE UNITED KINGDOM

 

Bertwistle D1, Anderson P2, Jofre-Bonet M3
1IMS Health, London, UK, 2Swansea University/Prifysgol Abertawe, Swansea/Abertawe, UK, 3City University London, London, UK

PCN138

PATTERNS OF ANTICOAGULANT USE IN CANCER PATIENTS RECEIVING CHEMOTHERAPY

 

Zong JH1, Eckert L2, Zhang L1, Dai WS1, Lyman GH3, Cohen AT4
1Sanofi R&D, Bridgewater, NJ, USA, 2Sanofi R&D, CHILLY-MAZARIN Cedex, France, 3Duke University, Durham, NC, USA, 4King's College Hospital, London, UK

PCN139

CHARACTERISTICS OF LONG-ACTING SOMATOSTATIN (SSA) USE IN GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE (GEP-NET) TUMORS IN THE NETHERLANDS

 

Bezemer ID1, Penning FJA1, Brulais S2, Verduyn CSC3, Herings RMC1
1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Ipsen pharma, Boulogne-Billancourt, France, 3Mapi Consultancy, Houten, The Netherlands

PCN140

THE EVALUATION OF HEALTH CARE RESOURCE UTILIZATION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER: RESULTS OF A MULTINATIONAL OBSERVATIONAL STUDY

 

Dass RN1, Hamberg P2, Spencer M3, Wheatley Price P1
1Janssen-Cilag, London, UK, 2Sint Franciscus Gasthuis, Rotterdam, The Netherlands, 3Janssen-Cilag Limited, High Wycombe, Bucks, UK

PCN141

HEALTH CARE UTILIZATION (HCU) BY BREAST CANCER (BC) AND NON-HODGKIN LYMPHOMA (NHL) PATIENTS WITH CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA (FN) IN THE NETHERLANDS

 

Issa DE1, van Herk-Sukel MPP2, Gelderblom H3, Houweling LMA2, Jager A4, De La Orden M5, Lugtenburg PJ4, van der Werf-Langenberg ME6, Nortier JWR3, de Jong FA6
1VU University Medical Center, Amsterdam, The Netherlands, 2PHARMO Institute, Utrecht, The Netherlands, 3Leiden University Medical Center, Leiden, The Netherlands, 4Erasmus University Medical Center, Rotterdam, The Netherlands, 5Amgen, Uxbridge, UK, 6Amgen BV, Breda, The Netherlands

PCN142

SUCCESS FACTORS FOR ACHIEVING REIMBURSEMENT FOR ONCOLOGY DRUGS IN AUSTRALIA

 

O'Leary BA, McElroy HJ, Manipis K
Covance Pty Ltd, North Ryde, NSW, Australia

PCN143

UTILITY DATA IN APPRAISALS OF ONCOLOGY DRUGS BY THE UK NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

 

Proudfoot C
Sanofi UK, Guildford, UK

PCN144

ACCESS TO CANCER INTERVENTIONS ACROSS THE UK: TO WHAT EXTENT DOES SMC ADVICE AGREE WITH NICE'S END-OF-LIFE THERAPIES?

 

Hamerslag L, Brooks-Rooney C
Costello Medical Consulting Ltd., Cambridge, UK

PCN145

OBSERVATIONAL MACRO ANALYSIS ON THE AGGREGATED CIGARETTE PRICE ELASTICITY IN DENMARK 1978-2010

 

Clemmensen KKB
Student at Copenhagen University, Copenhagen, Denmark

PCN146

TRENDS IN COMPUTED TOMOGRAPHY USE IN CANADA: LOW-DOSE IONIZING RADIATION AND THE POTENTIAL RELATED CANCER RISK

 

Zowall H1, Brewer C2, Deutsch A1
1McGill University, Montreal, QC, Canada, 2Zowall Consulting, Westmount, QC, Canada

PCN147

A CROSS EUROPEAN COMPARISON OF ERIBULIN REIMBURSEMENT DECISIONS

 

Walker SA1, Ando G2
1IHS, London, UK, 2IHS Global Insight, London, UK

PCN148

REVIEW OF NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE) RECOMMENDATIONS FOR ANTI-CANCER AGENTS ACROSS MULTIPLE DRUG-INDICATION COMBINATIONS

 

Chawla A1, Oza A1, Nellesen D1, Brown J2, Liepa AM3, Price G4, Nash-Smyth E4, Cuyun Carter G4, Boye ME4
1Analysis Group, Inc., Menlo Park, CA, USA, 2Eli Lilly and Company, Windlesham, Surrey, UK, 3Eli Lilly and Company and/or any of its subsidiaries, Indianapolis, IN, USA, 4Eli Lilly and Company, Indianapolis, IN, USA

PCN149

UNCERTAINTY REGARDING NICE'S END-OF-LIFE SMALL PATIENT POPULATION CRITERIA

 

Moïse P1, Sweeney N2, Holmstrom S3
1Quintiles Global Consulting, Levallois-Perret, Ile-de-France, France, 2Quintiles, Hoofddorp, The Netherlands, 3Astellas Pharma Global Development, Leiderdorp, The Netherlands

PCN150

COMPARISONS OF QALYS GAINED, COST PER QALY GAINED AND ASMRS FOR 38 ANTICANCER DRUGS IN FRANCE AND THE UNITED KINGDOM: VIVE LA DIFFERENCE?

 

Drummond M1, de Pouvourville G2, Haig J3, Jones EC4, Saba G2
1University of York, York, UK, 2Essec Business School, Cergy Pontoise, France, 3OptumInsight, Burlington, ON, Canada, 4OptumInsight, Uxbridge, UK

PCN151

HTAS FOR THE DEADLIEST DISEASES: WHAT CAN WE LEARN FROM MULTI-NATIONAL COMPARISONS OF ONCOLOGY AND CARDIOLOGY HEALTH TECHNOLOGY ASSESSMENTS?

 

Hughes KE, Shirkhorshidian I, Atlas M
Avalere Health LLC, Washington, DC, USA

PCN152

PATIENT-RELEVANT ENDPOINTS (PRE) IN ONCOLOGY - CURRENT ISSUES IN THE CONTEXT OF EARLY BENEFIT ASSESSMENT (EBA) IN GERMANY: AN INDUSTRY PERSPECTIVE

 

Dabisch I1, Dethling J2, Dintsios CM1, Drechsler M3, Kalanovic D4, Kaskel P5, Langer F6, Ruof J7, Ruppert T1, Wirth D8
1German Association of Research-based Pharmaceutical Companies (vfa), Berlin, Germany, 2GlaxoSmithKline GmbH & Co. KG, Munich, Germany, 3Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany, 4Pfizer Deutschland GmbH, Berlin, Germany, 5MSD Sharp Dohme GmbH, Haar (Munich), Germany, 6Lilly Deutschland GmbH, Bad Homburg, Germany, 7Medizinische Hochschule Hannover, Hannover, Germany, 8Janssen-Cilag GmbH, Neuss, Germany

PCN153

APPLICATION OF REAL WORLD DATA TO INFORM A BREAST CANCER DECISION - ANALYTIC MODEL IN AUSTRIA AND THE U.S - PRELIMINARY OUTCOMES OF DATA COLLECTION

 

Jahn B1, Stenehjem D2, Saverno KR3, Rochau U4, Cai B2, Siebert U5, Brixner D6
1UMIT - University for Health Sciences, Medical Informatics and Technology; Oncotyrol - Center for Personalized Cancer Medicine, Hall i.T.;Innsbruck, Tyrol, Austria, 2University of Utah, Salt Lake City, UT, USA, 3UMIT- Univ. for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria; Univ. of Utah, Salt Lake City, USA, Hall i.T.;Innsbruck, Tyrol, Austria, 4UMIT; Oncotyrol - Center for Personalized Cancer Medicine, Hall i.T.;Innsbruck, Tyrol, Austria, 5UMIT/ Oncotyrol/ Harvard University, Hall i.T.;Innsbruck, Tyrol, Austria, 6University of Utah, College of Pharmacy, Salt Lake City, UT, USA

PCN154

ARE POPULATION-BASED REGISTRIES A SUITABLE TOOL FOR OUTCOMES RESEARCH IN CANCER? EXPERIENCES FROM FOUR REGISTRIES

 

de Groot S, Blommestein H, Franken M, Uyl-de Groot C
Erasmus University Rotterdam, Rotterdam, The Netherlands

PCN155

IS SALE OF TOBACCO AND SMOKING PREVALENCE PREDICTORS OF FUTURE LUNG CANCER INCIDENCE?

 

Clemmensen KKB, Clemmensen IH
Danish Cancer Society, Copenhagen, Denmark

PCN156

VALUE BASED PRICING IN THE UK; INDUSTRY STAKEHOLDERS' PERSPECTIVES

 

Chate S1, McConkey D2, Mukku S3
1University of Cambridge, Cambridge, Cambridgeshire, UK, 2Double Helix Consulting, London, UK, 3Double Helix Consulting Group, London, UK

PCN157

CONCEPTUAL FRAMEWORK FOR THE EVALUATION OF PATIENT ACCESS SCHEMES (PAS) IN THE EU

 

Kiss Z1, Hortobagyi L1, Szegvari B2, Muszbek N3
1United BioSource Corporation, Budapest, Budapest, Hungary, 2UCB Hungary Ltd, Budapest, Budapest, Hungary, 3United BioSource Corporation, Budapest, Hungary

PCN158

ADHERENCE TO HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER2) TESTING & ADJUVANT TRASTUZUMAB TREATMENT GUIDELINES IN A CANADIAN PROVINCE

 

Ferrusi IL1, Trudeau M2, Earle CC3, Leighl N4, Pullenayegum E1, Khong H5, Hoch J6, Marshall D7
1McMaster University, Hamilton, ON, Canada, 2Sunnybrook Health Science Centre, Toronto, ON, Canada, 3Cancer Care Ontario / Institute for Cancer Research, Toronto, ON, Canada, 4Princess Margaret Hospital, Toronto, ON, Canada, 5Alberta Bone & Joint Health Institute, Calgary, AB, Canada, 6Cancer Care Ontario, Toronto, ON, Canada, 7University of Calgary, Calgary, AB, Canada

PCN159

MELODY BRAZIL - TREATMENT PATTERNS IN BRAZILIAN HEALTH CARE SYSTEM

 

Schmerling RA1, Barrios C2, Nita ME3, Stefani SD4, Campos E5, Nunes J6, Biasi L7, Lima L8, Dzik C9, Johnston K10, Santinho CS3, Donato BMK11
1Hospital São José – Beneficência Portuguesa de São Paulo, São Paulo , Brazil, 2School of Medicine, Pontifical University Catholic RS, Porto Alegre, Brazil, 3Bristol-Myers Squibb S/A, São Paulo, SP, Brazil, 4Hospital Mãe de Deus, Porto Alegre, RS, Brazil, 5Univille (Universidade da Região de Joinville), Joinville, Brazil, 6Hospital Cancer Barretos, Barretos, Brazil, 7Oncoville, Curitiba, Brazil, 8CEPON, Florianopolis, Brazil, 9Hospital Sirio Libanes, Sao Paulo, Brazil, 10Oxford Outcomes, Vancouver, BC, Canada, 11Bristol-Myers Squibb Company, Wallingford, CT, USA

SESSION III – TUESDAY, 6 NOVEMBER
SET-UP: Tuesday, 6 November 2012, 8:30 – 8:45
POSTER DISPLAY HOURS: Tuesday, 6 November 2012, 8:45 – 13:45
POSTER AUTHOR DISCUSSION HOUR: Tuesday, 6 November 2012, 12:45 – 13:45
DISMANTLE: Tuesday, 6 November 2012, 13:45

MUSCULAR-SKELETAL DISORDERS – Clinical Outcomes Studies

PMS1

CHARACTERISTICS OF PATIENTS WITH RHEUMATOID ARTHRITIS IN TURKEY: RESULTS FROM THE TURKISH LEAGUE AGAINST RHEUMATISM RA REGISTRY

 

Bal A1, Ataman S2, Turkish League Against Rheumatism RA Study Group TLAR3
1Diskapi YB Education and Research Hospital, Ankara, Turkey, 2Ankara University Medical Faculty, Ankara, Turkey, 3Turkish League Against Rheumatism, Ankara, Turkey

PMS2

IMPROVEMENTS IN PHYSICAL FUNCTION AND DISABILITY IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER TREATMENT WITH NNC0109-0012 (ANTI-IL-20 MAB) IN A PHASE 2A TRIAL

 

Senolt L1, Hansen BB2, Strandberg-Larsen M2, Dokoupilová E3
1Charles University, Prague, Czech Republic, 2Novo Nordisk A/S, Søborg, Denmark, 3Medical Plus s.r.o., Uherske Hradiste, Czech Republic

PMS3

IMPROVEMENTS IN PATIENT-REPORTED PAIN AND GLOBAL DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS AFTER TREATMENT WITH NNC0109-0012 (ANTI-IL-20 MAB) IN A PHASE 2A TRIAL

 

Senolt L1, Hansen BB2, Strandberg-Larsen M2, Dokoupilová E3
1Charles University, Prague, Czech Republic, 2Novo Nordisk A/S, Søborg, Denmark, 3Medical Plus s.r.o., Uherske Hradiste, Czech Republic

PMS4

COMPARING THE EFFICACY AND SAFETY OF BIOLOGICS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS: A NETWORK META-ANALYSIS

 

Janssen KJ1, Medic G1, Broglio K2, Bergman G3, Berry S2, Sabater FJ4, Sennfalt K5
1MAPI Consultancy, Houten, Utrecht, The Netherlands, 2Berry Consultants, Austin, TX, USA, 3MAPI Consultancy, Houten, The Netherlands, 4Bristol-Myers Squibb, Paris, Paris, France, 5Bristol-Myers Squibb, Rueil-Malmaison, France

PMS5

BENEFIT-RISK ANALYSIS OF ADALIMUMAB AND ALTERNATIVE TREATMENTS FOR MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS

 

Hicks KA1, Earnshaw SR2, Shaw JW3, Cifaldi M3
1RTI-Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3Abbott Laboratories, Abbott Park, IL, USA

PMS6

ANTI-TUMOUR NECROSIS FACTOR (TNF) DRUGS FOR THE TREATMENT OF PSORIATIC ARTHRITIS (PSA)

 

Farrell J1, Mills E2, Sheppard O3, Thorlund K4
1MSD, Hoddesdon, Hertfordshire, UK, 2University of Ottawa, Ottawa, ON, Canada, 3MSD Ltd., Hoddesdon, UK, 4McMaster University, Hamilton, ON, Canada

PMS7

BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS AND THE RISK OF NON-VERTEBRAL OSTEOPOROTIC FRACTURES IN PATIENTS WITH RHEUMATOID ARTHRITIS AGED 50 YEARS AND OVER

 

Roussy JP1, Bessette L2, Bernatsky S3, Rahme E3, Lachaine J1
1University of Montreal, Montreal, QC, Canada, 2CHUL, Quebec, QC, Canada, 3McGill UHC/RVH, Montreal, QC, Canada

PMS8

DUPUYTREN DISEASE IN ITALY: A STUDY BASED ON A GPS LONGITUDINAL PATIENT DATABASE

 

Heiman F, Katz P, Pegoraro V
CSD Medical Research S.r.l., Milan, Italy

MUSCULAR-SKELETAL DISORDERS – Cost Studies

PMS9

BUDGET IMPACT OF USING SUGAMMADEX FOR THE ROUTINE REVERSAL OF NEUROMUSCULAR BLOCKADE IN A GREEK HEALTH CARE SETTING

 

Insinga RP1, Konstantopoulou T2, Athanasakis K3, Argyris G4
1Merck & Co. Inc., Upper Gwynedd, PA, USA, 2Merck Sharp & Dohme S.A., Athens, Greece, 3National School of Public Health, Athens, Greece, 4Merck Sharp Dohme S.A., Athens, Greece

PMS10

COMPARING COSTS OF ANTI-TNF THERAPY BY ADMINSTRATION ROUTE FOR PATIENTS WITH ANKYLOSING SPONDYLITIS AND RHEUMATOID ARTHRITIS IN FRANCE IN 2012: A BUDGET IMPACT MODEL

 

Chevreul K1, Bourguignon S2, Granados D3
1Unité de Recherche Clinique Economie de la santé d'Ile-de-France, Paris, France, 2Stratégique Santé, Bondoufle, France, 3Abbott Laboratories, Rungis, France

PMS11

BUDGET IMPACT ANALYSIS IN SPANISH PATIENTS WITH DUPUYTREN'S CONTRACTURE: FASCIECTOMY VERSUS COLLAGENASE CLOSTRIDIUM HISTOLYTICUM

 

de Salas-Cansado M1, Cuadros M2, Arandes JM3, del Cerro M4, Muñoz R5, Lwoff N5
1Pfizer Spain, Alcobendas, Madrid, Spain, 2Hospital Virgen de la Victoria, Málaga, Spain, 3Hospital Clìnic, Barcelona, Spain, 4Hospital Beata María, Madrid, Spain, 5Pfizer Spain, Alcobendas, Madrid, Spain

PMS12

BUDGET IMPACT OF GOLIMUMAB IN THE ANTI-TNF TREATMENT OF RHEUMATOID ARTHRITIS, AKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM

 

Morais AD, Pereira ML
Janssen Cilag Farmaceutica, São Paulo, Brazil

PMS13

COMPARATIVE BUDGET IMPACT OF TERIPARATIDE VERSUS PARATHORMONE 1-84 USING INDIRECT COMPARISON EFFICACY DATA IN ITALY

 

Migliore A1, Broccoli S2, Bizzi E1, Piscitelli P3
1S.Pietro FBF Hospital, Rome, italy, Italy, 2BIOIKOS, Bologna, Italy, Italy, 3ISBEM institute of research, Pescara, italy, Italy

PMS14

IMPACT OF SEVERITY INDEX FOR RHEUMATOID ARTHRITIS ON HEALTH CARE COSTS AND UTILIZATIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS

 

Baser O1, Wang L2, Du J3, Wang H3, Xie L3
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research, Dallas, TX, USA, 3STATinMED Research, Ann Arbor, MI, USA

PMS15

DETERMINANTS OF TOTAL HEALTH CARE COSTS ASSOCIATED WITH ANKYLOSING SPONDYLITIS PREVALENT CASES IN TURKEY

 

Baser O1, Burkan A2, Baser E3, Koselerli R2, Ertugay E2, Altinbas A4
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2Social Security Institution, Ankara, Turkey, 3STATinMED Research, Istanbul, MI, Turkey, 4Dýskapý Yýldýrým Beyazýt Education and Research Hospital, Ankara, Turkey

PMS16

ECONOMIC BURDEN OF JUVENILE IDIOPATHIC ARTHRITIS IN RUSSIA

 

Derkach EV1, Omelyanovsky V2, Avxentyeva M2, Ivakhnenko O2, Ignateva V2
1Russian State Medical University, Moscow, Russia, 2Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National Research Medical University, Moscow, Russia

PMS17

THE SOCIETAL COST FOR RA BEFORE AND AFTER THE INTRODUCTION OF BIOLOGICAL DRUGS- A SWEDISH NATIONAL REGISTER STUDY FOR 1990-2010

 

Kalkan A, Husberg M, Hallert E, Bernfort L, Carlsson P
Institution of medicine and health, Linköping University, Linköping, Sweden

PMS18

IMPORTANCE OF COI STUDIES IN THE HEALTH CARE-RELATED DECISION-MAKING PROCESS THROUGH THE EXAMPLE OF RHEUMATOID ARTHRITIS

 

Nagy B1, Kovacs E2, Radnai A3, Jozsa G4
1Healthware Ltd, Budapest, Hungary, 2Healthware Consulting Ltd., Budapest, Hungary, 3Abbott Laboratories, Budapest, Hungary, 4University of Western Hungary, Sopron, Hungary

PMS19

INDIRECT COSTS ASSOCIATED WITH ANKYLOSING SPONDYLITIS IN TURKEY

 

Akkoç N1, Direskeneli H2, Erdem H3, Gül A4, Kabasakal Y5, Kiraz S6, Durguner B7, Baser O8, Hamuryudan V9
1Dokuz Eylül University, Izmir, Turkey, 2Marmara University Faculty of Medicine, Istanbul, Turkey, 3Gulhane Military Medical Academy, Ankara, Turkey, 4Istanbul University, Istanbul, Turkey, 5Ege University, Izmir, Turkey, 6Hacettepe University, Ankara, Turkey, 7Pfizer Pharmaceuticals, Istanbul, Turkey, 8STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 9Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey

PMS20

TOTAL HEALTH CARE COSTS ASSOCIATED WITH RHEUMATOID ARTHRITIS INCIDENT CASES IN TURKEY

 

Baser O1, Burkan A2, Baser E3, Koselerli R2, Ertugay E2, Altinbas A4
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2Social Security Institution, Ankara, Turkey, 3STATinMED Research, Istanbul, MI, Turkey, 4Dýskapý Yýldýrým Beyazýt Education and Research Hospital, Ankara, Turkey

PMS21

DETERMINANTS OF TOTAL HEALTH CARE COSTS ASSOCIATED WITH RHEUMATOID ARTHRITIS PREVALENT CASES IN TURKEY

 

Baser O1, Burkan A2, Baser E3, Koselerli R2, Ertugay E2, Altinbas A4
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2Social Security Institution, Ankara, Turkey, 3STATinMED Research, Istanbul, MI, Turkey, 4Dýskapý Yýldýrým Beyazýt Education and Research Hospital, Ankara, Turkey

PMS22

INDIRECT COSTS ASSOCIATED WITH RHEUMATOID ARTHRITIS IN TURKEY

 

Hamuryudan V1, Direskeneli H2, Ertenli I3, Inanç M4, Karaaslan Y5, Oksel F6, Özbek S7, Pay S8, Terzioglu E9, Durguner B10, Baser O11, Akkoç N12
1Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey, 2Marmara University Faculty of Medicine, Istanbul, Turkey, 3Hacettepe University Faculty of Medicine, Ankara, Turkey, 4Istanbul University, Istanbul, Turkey, 5Ankara Numune Training and Research Hospital, Ankara, Turkey, 6Ege University, Izmir, Turkey, 7Cukurova University, Adana, Turkey, 8Gulhane Military Medical Academy, Ankara, Turkey, 9Akdeniz University, Antalya, Turkey, 10Pfizer Pharmaceuticals, Istanbul, Turkey, 11STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 12Dokuz Eylül University, Izmir, Turkey

PMS23

TOTAL HEALTH CARE COSTS ASSOCIATED WITH ANKYLOSING SPONDYLITIS INCIDENT CASES IN TURKEY

 

Baser O1, Burkan A2, Baser E3, Koselerli R2, Ertugay E2, Altinbas A4
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2Social Security Institution, Ankara, Turkey, 3STATinMED Research, Istanbul, MI, Turkey, 4Dýskapý Yýldýrým Beyazýt Education and Research Hospital, Ankara, Turkey

PMS24

DIRECT AND PRODUCTIVITY COSTS OF RHEUMATOID ARTHRITIS IN THE SLOVAK REPUBLIC – COST-OF-ILLNESS STUDY

 

Dolezal T, Klimes J, Vocelka M
Institute of Health Economics and Technology Assessment, Prague, Czech Republic

PMS25

STRUCTURE OF DIRECT COST OF CARE OF PATIENTS TREATED FOR SEVERE RHEUMATOID ARTHRITIS IN FRANCE

 

Fagnani F1, Laurendeau C1, Fautrel B2, Joubert JM3, Cukierman G3, Gourmelen J4
1Cemka-Eval, Bourg la Reine, France, 2Rheumatology, Paris VI University, Paris, France, 3UCB Pharma, Colombes, France, 4Inserm u1018, Villejuif, France

PMS26

ASSESSMENT OF THE BURDEN OF RHEUMATOID ARTHRITIS IN FRANCE: ANALYSIS OF A NATIONAL REPRESENTATIVE CLAIM DATABASE

 

Fagnani F1, Laurendeau C1, Fautrel B2, Joubert JM3, De Chalus T3, Gourmelen J4
1Cemka-Eval, Bourg la Reine, France, 2Rheumatology, Paris VI University, Paris, France, 3UCB Pharma, Colombes, France, 4Inserm u1018, Villejuif, France

PMS27

THE METHOD FOR REVERSING ANTICOAGULATION AFFECTS TREATMENT COSTS AND MAY DECREASE MORTALITY AMONG HIP FRACTURE PATIENTS USING WARFARIN

 

Agthe N1, Purmonen T1, Kokki H2
1Oy Medfiles Ltd, Kuopio, Finland, 2Kuopio University Hospital, Kuopio, Finland

PMS28

COST-BENEFIT-ANALYSIS OF THROMBOPROPHYLAXIS WITH RIVAROXABAN AND CERTOPARIN-SODIUM IN PATIENTS AFTER TOTAL HIP OR KNEE REPLACEMENT

 

Heidorn K, Mittelmeier W, Kundt G, Skripitz R
Universitätsmedizin Rostock, Rostock, Germany

PMS29

COST EFFECTIVENESS OF ADALIMUMAB VERSUS GOLIMUMAB AND PLACEBO IN ANKYLOSING SPONDYLITIS IN ITALY

 

Marcellusi A1, Botteman MF2, Rao S3, Cifaldi M3, Solem CT4, Gitto L1, Giannantoni P1, Mennini FS1
1University of Rome, Rome, Italy, 2Pharmerit North America, LLC., Bethesda, MD, USA, 3Abbott Laboratories, Abbott Park, IL, USA, 4Pharmerit International, Bethesda, MD, USA

PMS30

PHARMACOECONOMIC EVALUATION OF TOCILIZUMAB MONOTHERAPY VERSUS ADALIMUMAB MONOTHERAPY IN REDUCING DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS

 

Navarro Sarabia F1, Blanco FJ2, Álvaro-Gracia J3, García Meijide J4, Poveda J5, Ruiz-Beato E6
1H. Universitario Virgen Macarena, Sevilla, Andalucia, Spain, 2INIBIC-Hospital Universitario A Coruña, A Coruña, Galicia, Spain, 3H. Universitario La Princesa, Madrid, Madrid, Spain, 4H. Ntra. Sra. La Esperanza, Santiago de Compostela, Galicia, Spain, 5Hospital Universitario La Fe, Valencia, Valencia, Spain, 6Roche Farma, S.A., Madrid, Madrid, Spain

PMS31

ECONOMIC EVALUATION OF ADALIMUMAB VERSUS OTHER BIOLOGIC TREATMENTS FOR MODERATE TO SEVERE PSORIATIC ARTHRITIS IN ITALY

 

Marcellusi A1, Bansback N2, Rao S3, Cifaldi M3, Gitto L1, Giannantoni P1, Russo S4, Mennini FS1
1University of Rome, Rome, Italy, 2Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, 3Abbott Laboratories, Abbott Park, IL, USA, 4University of Rome , Rome, Italy

PMS32

COST-EFECTIVENESS ANALYSIS OF ANTI-OSTEOPOROTIC THERAPY AMONG KOREAN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS

 

Oh Y1, Kang HY2, Moon SH1, Suh HS2
1Yonsei University, Seoul, South Korea, 2College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, South Korea

PMS33

COST-EFFICACY ANALYSIS OF BIOLOGIC DRUGS IN COMBINATION WITH DMARDS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO TRADITIONAL DMARDS IN PORTUGAL – A SIMPLIFIED APPROACH

 

Cafe A1, Monteiro I1, Loff JF2, Encarnação R1
1Roche Farmacêutica Química, Lda., Amadora, Portugal, 2phiStat, Lisbon, Portugal

PMS34

COST-EFFECTIVENESS ANALYSIS OF BEMIPARIN AS PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM IN TOTAL KNEE REPLACEMENT SURGERY IN MEXICO

 

Carlos F1, Aguirre A2, Esquivel R3, Nettel J4, Meillon L5, Bierschwale H2
1R A C Salud Consultores S.A. de C.V., Mexico City, Mexico, 2UCB Pharma, Mexico City, Mexico, 3IMSS, Lomas Verdes, Estado de México, Naucalpan, Mexico, 4IMSS, Queretaro, Mexico, 5IMSS CMN Siglo XXI, Mexico City, Mexico

PMS35

COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS (RA) PATIENTS WITH INADEQUATE RESPONSE TO ANTI-TNF TREATMENT IN TURKEY

 

Ertenli I
Hacettepe University Faculty of Medicine, Ankara, Turkey

PMS36

COST-EFFECTIVENESS OF DENOSUMAB FOR THE TREATMENT OF ELDERLY WOMEN WITH POST-MENOPAUSAL OSTEOPOROSIS IN SWEDEN

 

Lundkvist J1, Löthgren M2, Badamgarav E2, Freyschyss B1
1Amgen, Solna, Sweden, 2Amgen (Europe) GmbH, Zug, Switzerland

PMS37

ECONOMIC EVALUATION MODEL OF BIOLOGIC THERAPIES FOR MODERATE TO SEVERE PSORIATIC ARTHRITIS IN GERMANY

 

Wang X1, Bansback N1, Anis A1, Joshi AD2, Rao S2, Wolff M3, Cifaldi M2
1University of British Columbia, Vancouver, BC, Canada, 2Abbott Laboratories, Abbott Park, IL, USA, 3Abbott GmbH & Co. KG, Ludwigshafen, Germany

PMS38

COST-EFFECTIVENESS OF TAPENTADOL FOR SEVERE CHRONIC NON-CANCER PAIN IN BELGIUM

 

Obradovic M1, Ikenberg R2, Hertel N3, Liedgens H1
1Grünenthal GmbH, Aachen, Germany, 2IMS Health, Munich, Germany, 3IMS Health, London, UK

PMS39

COST-EFFECTIVENESS ANALYSIS OF CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATHOID ARTHRITIS FROM A BRAZILIAN PRIVATE PERSPECTIVE

 

Piha T1, Meirelles EDS2, Kuriki W3, Miranda PA1
1AstraZeneca, Cotia, São Paulo, Brazil, 2HC-FMUSP, Sao Paulo, São Paulo, Brazil, 3AstraZeneca, Cotia, Brazil

PMS40

COST-EFFECTIVENESS OF DENOSUMAB FOR THE TREATMENT OF MALE OSTEOPOROSIS (MOP) IN THE ELDERLY IN SWEDEN

 

Parthan A1, Deflin MM1, Agodoa I2, Tao CY1, Silverman SL3, Orwoll E4
1OptumInsight, Medford, MA, USA, 2Amgen Inc., Thousand Oaks, CA, USA, 3Cedars-Sinai Hospital, Beverly Hills, CA, USA, 4Oregon Health & Science University, Portland, OR, USA

PMS41

COST-EFFECTIVENESS OF DENOSUMAB IN PREVENTING OSTEOPOROTIC FRACTURES IN POSTMENOPAUSAL WOMEN FROM THE PRIVATE HEALTH CARE SETTING PERSPECTIVE IN BRAZIL

 

Barbosa EG1, Machado M1, Araújo GTBD2, Etto H2, Fonseca M3, Olimpio A1
1GlaxoSmithKline Ltda, Rio de Janeiro, Rio de Janeiro, Brazil, 2Axia.Bio, São Paulo, São Paulo, Brazil, 3Federal University of São Paulo / Axia.Bio Consulting, São Paulo, Brazil

PMS42

COST-UTILITY OF TOCILIZUMAB MONOTHERAPY IN METHOTREXATE INTOLERANT/CONTRA-INDICATED, MODERATE/SEVERE RHEUMATOID ARTHRITIS PATIENTS IN PORTUGAL

 

Monteiro I1, Cafe A1, Encarnação R1, Diamantopoulos A2, Dejonckheere F3
1Roche Farmacêutica Química, Lda., Amadora, Portugal, 2Symmetron Limited, Elstree, Herts, UK, 3F. Hoffmann-La Roche Ltd., Basel, Switzerland

PMS43

COST-EFFECTIVENESS OF TOCILIZUMAB MONOTHERAPY VERSUS ADALIMUMAB MONOTHERAPY IN THE TREATMENT OF SEVERE ACTIVE RA

 

Carlson JJ1, Ogale S2, Dejonckheere F3, Sullivan SD4
1University of Washington, Seattle, WA, USA, 2Genentech, South San Francisco, CA, USA, 3F. Hoffmann-La Roche Ltd., Basel, Switzerland, 4University of Washington, Seattle , WA, USA

PMS44

COST-EFFECTIVENESS OF ALENDRONATE THERAPY FORCORTICOSTEROID-INDUCED OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN WITH RHEUMATOID ARTHRITIS IN JAPAN

 

Moriwaki K1, Noto S1, Inoue H1, Yanagisawa S2
1Niigata University of Health and Welfare, Niigata, Japan, 2Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Himeji, Japan

PMS45

EXERCISE THERAPY, MANUAL THERAPY, OR BOTH, FOR MANAGEMENT OF OSTEOARTHRITIS OF THE HIP OR KNEE: ECONOMIC EVALUATION ALONGSIDE A RANDOMIZED CLINICAL TRIAL

 

Abbott JH1, Pinto D2, Robertson MC1, MOA Trial Team T1
1University of Otago, Dunedin, Otago, New Zealand, 2Northwestern University, Chicago, MI, USA

PMS46

ECONOMIC EVALUATION OF ADALIMUMAB FOR THE TREATMENT OF EARLY- AND LATE-STAGE RHEUMATOID ARTHRITIS IN ITALY

 

Benedict A1, Kongnakorn T2, Shaw JW3, Marcellusi A4, Vanness DJ5, Gitto L4, Giannantoni P4, Cifaldi M3, Attinà G6, Mennini FS4
1United BioSource Corporation, Budapest, Hungary, 2United BioSource Corporation, London, UK, 3Abbott Laboratories, Abbott Park, IL, USA, 4University of Rome, Rome, Italy, 5United BioSource Corporation, Bethesda, MD, USA, 6Abbott Italy, Latina, Italy

PMS47

THE HEALTH AND ECONOMIC CONSEQUENCES OF DELAY IN STARTING DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) IN RHEUMATOID ARTHRITIS

 

Van Doornum S1, Roberts L2, Reed MD3, Liew D1
1The University of Melbourne, Parkville, Vic, Australia, 2James Cook University, Douglas, Queensland, Australia, 3Sir Charles Gairdiner Hospital, Nedlands, Western Australi, Australia

PMS48

TOCILIZUMAB IN METHOTREXATE-INTOLERANT OR CONTRAINDICATED PATIENTS – A COST-UTILITY MODEL FOR THE UNITED KINGDOM

 

Harland D1, Gibbons C1, Diamantopoulos A2, Pang H1, Huertas C1, Dejonckheere F3
1Roche Products Limited, Welwyn Garden City, UK, 2Symmetron Limited, London, UK, 3F. Hoffmann-La Roche Ltd., Basel, Switzerland

PMS49

COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT AND INFLIXIMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN SPAIN

 

Guijarro P1, Crespo C2, Brosa M2
1Pfizer Spain, Alcobendas, Madrid, Spain, 2Oblikue Consulting, Barcelona, Spain

PMS50

INDIRECT COSTS OF RHEUMATOID ARTHRITIS IN SERBIA RELATED TO WORK ABSENTEEISM, MEDICAL WELFARE AND REHABILITATION COSTS

 

Damjanov N1, Vojinovic J2
1School of Medicine, University of Belgrade, Belgrade, Serbia and Montenegro, 2School of Medicine, University of Nis, Nis, Serbia and Montenegro

PMS51

WORK PRODUCTIVITY AND PRODUCTIVITY COSTS OF PATIENTS WITH RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIASIS IN THE CZECH REPUBLIC

 

Kruntoradova K1, Klimes J2, Dolezal T2, Vocelka M2, Petrikova A3
1Czech Technical University in Prague, Faculty of Biomedical Engineering, Kladno, Czech Republic, 2Institute of Health Economics and Technology Assessment, Prague, Czech Republic, 3VFU Brno, Brno, Czech Republic

PMS52

DRUG USE PROFILE IN A RHEUMATOID ARTHRITIS PATIENT COHORT: A BRAZILIAN HEALTH MANAGEMENT ORGANIZATION EXPERIENCE

 

Cantanheda CRDO, Simas HS, Dias QCP
Unimed-Rio Cooperativa de Trabalho Médico, Rio de Janeiro, Rio de Janeiro, Brazil

MUSCULAR-SKELETAL DISORDERS – Patient-Reported Outcomes & Patient Preference Studies

PMS53

ASSOCIATION BETWEEN TERIPARATIDE ADHERENCE AND HEALTH CARE UTILIZATION AND COSTS IN REAL WORLD U.S. KYPHOPLASTY/VERTEBROPLASTY PATIENTS

 

Zhao Y1, Johnston SS2, Smith D2, McMorrow D3, Krege JH1, Krohn K4
1Eli Lilly and Company, Indianapolis, IN, USA, 2Thomson Reuters, Washington, DC, USA, 3Thomson Reuters, Cambridge, MA, USA, 4Lilly USA, LLC, Indianapolis, IN, USA

PMS54

A RETROSPECTIVE COHORT STUDY OF PERSISTENCE & COMPLIANCE TO TREATMENT FOR OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN IN HUNGARY

 

Lakatos P1, Tóth E2, Kovacs E2, Lang Z2, Psachoulia E3, Intorcia M3
1Semmelweis University, Budapest, Hungary, 2Healthware Consulting Ltd., Budapest, Hungary, 3Amgen (Europe) GmbH, Zug, Switzerland

PMS55

A RETROSPECTIVE COHORT STUDY OF PERSISTENCE & COMPLIANCE TO TREATMENT FOR OSTEOPOROTIC MEN IN HUNGARY

 

Lakatos P1, Tóth E2, Kovacs E2, Lang Z2, Psachoulia E3, Intorcia M3
1Semmelweis University, Budapest, Hungary, 2Healthware Consulting Ltd., Budapest, Hungary, 3Amgen (Europe) GmbH, Zug, Switzerland

PMS56

IMPACT OF COMPLIANCE ON FRACTURE RISK FOR OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN IN HUNGARY

 

Lakatos P1, Tóth E2, Kovacs E2, Lang Z2, Psachoulia E3, Intorcia M3
1Semmelweis University, Budapest, Hungary, 2Healthware Consulting Ltd., Budapest, Hungary, 3Amgen (Europe) GmbH, Zug, Switzerland

PMS57

EFFECT OF DIFFERENT METHODS ON ESTIMATING PERSISTENCE TO ORAL BISPHOSPHONATE THERAPY IN PORTUGUESE PMO PATIENTS – AN OBSERVATIONAL PROSPECTIVE STUDY

 

Guerreiro J1, Torre C1, Mendes Z1, Machado M2, Ferreira I3, Feudjo-Tepie M4, Canhão H5, Branco J6, Miranda A1, Cristino J2
1INFOSAÚDE, Lisboa, Estremadura, Portugal, 2Amgen Portugal, Paço D'Arcos, Lisboa, Portugal, 3Amgen, Cambridge, Cambridge, UK, 4Amgen, Uxbridge, Uxbridge, UK, 5Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal, 6Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Lisboa, Portugal

PMS58

FREQUENCY OF ADMINISTRATION OF BIOLOGICS HAS AN IMPACT ON TREATMENT DECISION MAKING

 

Chevalier P1, Black CM2, Lamotte M3, Crombach J4, Huismans J4, Rosiek R5, Fan T6
1IMS Health, Vilvoorde, Belgium, 2St. John's University, Queens, NY, USA, 3IMS Health Consulting Group, Vilvoorde, Belgium, 4Merck Sharp & Dohme The Netherlands, Haarlem, The Netherlands, 5Medithuis B.V., MAARSSEN, BB , The Netherlands, 6Merck & Co. Inc., Whitehouse Station, NJ, USA

PMS59

IMPACT OF COMORBIDITIES ON MEASURING INDIRECT UTILITY BY THE MEDICAL OUTCOMES STUDY SHORT FORM 6D IN LOWER-LIMB OSTEOARTHRITIS

 

Hosseini K1, Gaujoux-Viala C2, Coste J1, Pouchot J1, Fautrel B3, Rat AC1, Guillemin F1
1Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, 2Paris 6 – Pierre et Marie Curie University; Department of Rheumatology, Pitié-Salpêtrière Hospital, Paris, France, 3Rheumatology, Paris VI University, Paris, France

PMS60

THE TIME HORIZON MATTERS: EXPLORATORY RESULTS VARYING THE TIME HORIZON IN TIME TRADE-OFF AND STANDARD GAMBLE UTILITY ELICITATION

 

Matza L1, Boye KS2, Feeny DH3, Bowman L2, Johnston JA2, McDaniel K1, Jordan J1, Devine MK1, Davies E4
1United BioSource Corporation, Bethesda, MD, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3University of Alberta, Portland, OR, USA, 4United BioSource Corporation, London, UK

PMS61

HEALTH-RELATED QUALITY OF LIFE AFTER VERTEBRAL FRACTURE: DIFFERENCES BETWEEN THE EQ-5D AND TIME-TRADE-OFF INSTRUMENTS

 

Willers C1, Alekna V2, Bianchi ML3, Clarck P4, Curiel MD5, Dimai HP6, Hernlund E1, Lesnyak O7, Svedbom A1, Thomas T8, Borgstrom F9
1OptumInsight, Stockholm, Sweden, 2Vilnius Unversity, Vilnius, Lithuania, 3Istituto Auxologico Italiano IRCCS, Milan, Italy, 4Hospital Infantil Federico Gómez and Faculty of Medicine UNAM, Mexico City, Mexico, 5Fundación Jimenez Diaz, Madrid, Spain, 6Medical University of Graz, Graz, Switzerland, 7Ural State Medical Academy, Yekaterinburg, Russia, 8INSERM U1059, Saint-Etienne, France, 9Karolinska Institutet, Stockholm, Sweden

PMS62

NOMINAL GROUP TECHNIQUE TO SELECT ATTRIBUTES FOR DISCRETE CHOICE EXPERIMENTS

 

Hiligsmann M1, Van Durme C1, Geusens P1, Dellaert B2, Dirksen C1, Van der Weijden T1, Reginster JY3, Boonen A1
1Maastricht University, Maastricht, The Netherlands, 2Erasmus University Rotterdam, Rotterdam, The Netherlands, 3University of Liège, Liège, Belgium

PMS63

ASSESSMENT OF THE OSTEOPOROSIS SELF-EFFICACY SCALE IN RELATION TO OSTEOPROTECTIVE BEHAVIORS AMONG TYPE 2 DIABETICS PATIENTS IN NORTH MALAYSIA

 

Abdulameer SA1, Syed Sulaiman SA1, Hassali MA1, Subramaniam K2, Sahib MN1
1Universiti Sains Malaysia, Minden, Penang, Malaysia, 2Penang General Hospital, George Town, Penang, Malaysia

PMS64

COMPARATIVE EFFICACY OF TOCILIZUMAB AND ATNF BIOLOGIC MONOTHERAPIES ON PATIENT REPORTED OUTCOMES (PROS) IN RA PATIENTS WHO HAVE SHOWN AN INADEQUATE RESPONSE TO CONVENTIONAL DMARDS (DMARD-IR): A NETWORK META-ANALYSIS

 

Buckley F1, Ogale S2, Dejonckheere F3, Jansen JP1
1MAPI Consultancy, Boston, MA, USA, 2Genentech, South San Francisco, CA, USA, 3F. Hoffmann-La Roche Ltd., Basel, Switzerland

PMS65

DETECTING POTENTIAL FIBROMYALGIA PATIENTS IN PRIMARY CARE SETTINGS: VALIDATION OF THE FIBRODETECT SCREENING TOOL

 

Gilet H1, Dias-Barbosa C1, Guillemin I1, Baron R2, Perrot S3, Alegre C4, Choy E5, Cruccu G6, Desmeules J7, Margaux J8, Richards S9, Serra E10, Spaeth M11, Arnould B1
1MAPI Consultancy, Lyon, France, 2Christian-Albrechts University, Kiel, Germany, 3Hospital Hotel Dieu, Paris, France, 4Hospital Universitari Valle d'Hebron, Barcelona, Spain, 5Cardiff University, Cardiff, UK, 6La Sapienza University, Roma, Italy, 7Geneva University Hospital, Geneva, Switzerland, 8Erasme Hospital, Brussels, Belgium, 9Poole Hospital NHS Trust, Poole, UK, 10Amiens University Hospital, Amiens, France, 11Center for Clinical Rheumatology, Gräfelfing, Germany

PMS66

THE MYOTONIC DYSTROPHY TYPE-1 HEALTH INDEX (MDHI): AN ANALYSIS OF ITS ABILITY TO DIFFERENTIATE BETWEEN CLINICALLY DISTINCT POPULATIONS

 

Heatwole C1, Bode R2, Dekdebrun J1, Dilek N1, Johnson N1, Luebbe E1, Martens W1, Thornton C1, Moxley RT1
1The University of Rochester, Rochester, NY, USA, 2Rehabilitation Institute of Chicago, Chicago, IL, USA

PMS67

LONG-TERM BENEFITS OF 4-WEEKLY CERTOLIZUMAB PEGOL COMBINATION AND MONOTHERAPY ON HOUSEHOLD PRODUCTIVITY AND SOCIAL PARTICIPATION IN RHEUMATOID ARTHRITIS: 5 YEAR RESULTS FROM AN OPEN LABEL EXTENSION STUDY

 

Strand V1, Purcaru O2, van Vollenhoven R3, Choy E4, Fleischmann R5
1Stanford University, Palo Alto, CA, USA, 2UCB Pharma, Brussels, Belgium, 3Karolinska University Hospital, Stockholm, Sweden, 4Cardiff University School of Medicine, Cardiff, UK, 5Metroplex Clinical Research Center, Dallas, TX, USA

MUSCULAR-SKELETAL DISORDERS – Health Care Use & Policy Studies

PMS68

THE USE OF MONITORING SYSTEMS TO BETTER REGULATE DRUG CONSUMPTION IN HUNGARIAN HOSPITALS

 

Ecseki A, Becsi R, Toth I, Rozsa P, Gerencser Z
MediConcept Ltd., Budapest, Hungary

PMS69

KEY DRIVERS FOR PRICING AND REIMBURSEMENT FOR BIOLOGIC DRUGS IN FRANCE

 

Niklitschek T1, Williams AE2, Storer M3
1University of Cambridge, Cambridge, UK, 2MedImmune Limited, Cambridge, UK, 3PriceSpective, London, UK

PMS70

UTILIZATION OF PAIN MEDICATIONS AMONG OSTEOARTHRITIS PATIENTS WHO INITIATED DULOXETINE AND STANDARD OF CARE FOR PAIN MANAGEMENT

 

Peng X1, Chen SY2, Wu N2, Yu X2, Andrews JS1, Novick D3
1Eli Lilly and Company, Indianapolis, IN, USA, 2United BioSource Corporation, Lexington, MA, USA, 3Eli Lilly and Company, Windlesham, Surrey, UK

PMS71

UTILIZATION OF DULOXETINE AND CELECOXIB IN OSTEOARTHRITIS PATIENTS

 

Andrews JS1, Wu N2, Chen SY2, Yu X2, Peng X1, Novick D3
1Eli Lilly and Company, Indianapolis, IN, USA, 2United BioSource Corporation, Lexington, MA, USA, 3Eli Lilly and Company, Windlesham, Surrey, UK

PMS72

ADHERENCE AND CHANGE OF OPIOID USE AFTER INITIATING DULOXETINE OR CELECOXIB AMONG PATIENTS WITH OSTEOARTHRITIS

 

Peng X1, Wu N2, Chen SY2, Yu X2, Andrews JS1, Novick D3
1Eli Lilly and Company, Indianapolis, IN, USA, 2United BioSource Corporation, Lexington, MA, USA, 3Eli Lilly and Company, Windlesham, Surrey, UK

PMS73

VISUALIZING TREATMENT PATTERNS OF VETERAN PATIENTS WITH RHEUMATOID ARTHRITIS WHO INITIATED TUMOR NECROSIS FACTOR THERAPY

 

Wang L1, Xie L2, Li L1, Huang A1, Wang H2, Baser O3
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research, Ann Arbor, MI, USA, 3STATinMED Research/The University of Michigan, Ann Arbor, MI, USA

PMS74

APPLICATION OF DATA VISUALIZATION TOOL: TREATMENT PATTERNS OF VETERAN PATIENTS WITH ANKYLOSING SPONDYLITIS WHO INITIATED TUMOR NECROSIS FACTOR THERAPY

 

Baser O1, Wang L2, Li L2, Huang A2, Wang H3, Xie L3
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research, Dallas, TX, USA, 3STATinMED Research, Ann Arbor, MI, USA

PMS75

REAL-WORLD UTILIZATION PATTERNS OF RHEUMATOID ARTHRITIS MEDICATIONS IN THE UNITED STATES: ANTI-TNF MONOTHERAPY AND ADHERENCE WITH NON-BIOLOGIC DMARDS IN COMBINATION WITH ANTI-TNF THERAPY

 

Engel-Nitz NM1, Ogale S2, Kulakodlu M1
1OptumInsight, Eden Prairie, MN, USA, 2Genentech, South San Francsico, CA, USA

PMS76

PATIENT ACCESS TO BIOLOGICS IN RHEUMATOID ARTHRITIS: THE VIEWS OF HEALTH CARE STAKEHOLDERS IN PORTUGAL

 

Laires P1, Mesquita R2, Veloso L3, Martins AP1, Cernadas R4, Fonseca JE5
1Merck, Sharp & Dohme, Oeiras, Portugal, 2Merck, Sharp & Dohme, Paço de Arcos, Portugal, 3Eurotrials, Lisbon, Portugal, 4ARS Norte, Oporto, Portugal, 5Faculty of Medicine (University of Lisbon), Lisbon, Portugal

PMS77

REAL-WORLD COMPARISON OF HEALTH CARE UTILIZATION BETWEEN DULOXETINE INITIATORS AND PREGABALIN INITIATORS AMONG FIBROMYALGIA PATIENTS

 

Peng X1, Sun P2, Wu A3, Andrews JS1, Novick D4, Faries D1, Sun S5
1Eli Lilly and Company, Indianapolis, IN, USA, 2Kailo Research Group, Fishers, IN, USA, 3Kailo Research Group, Los Angeles, CA, USA, 4Eli Lilly and Company, Windlesham, Surrey, UK, 5Kailo Research Group, Fremont, CA, USA

PMS78

DEMOGRAPHİC AND SOCİOECONOMİC CHARACTERİSTİCS THAT AFFECT SELECTİON OF İNTRAVENOUS VERSUS SUBCUTANEOUS İNJECTİON TUMOR NECROSIS FACTOR INHİBITORS FOR RHEUMATOID ARTHRITIS PATIENTS

 

Baser O1, Wang L2, Lewis-Beck C3, Wang H3, Li L2, Xie L3
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research, Dallas, TX, USA, 3STATinMED Research, Ann Arbor, MI, USA

PMS79

EVALUATION OF CURRENT HEALTH TECHNOLOGY ASSESSMENTS FOR RHEUMATOID ARTHRITIS – AN INSIGHT INTO THE KEY UNCERTAINTIES GENERATED BY THE AVAILABLE EVIDENCE

 

Sweeney N1, Heemstra L1, Hansen K2, Adalsteinsson JE2
1Quintiles, Hoofddorp, The Netherlands, 2Novo Nordisk A/S, Søborg, Denmark

PMS80

BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS – ELIGIBILITY CRITERIA IN THE UNITED KINGDOM

 

Lebmeier M, Righetti C
Bristol-Myers Squibb Company, Uxbridge, Middlesex, UK

PMS81

COST-EFFECTIVENESS AND BUDGET IMPACT OF CERTOLIZUMAB PEGOL AGAINST A MIX OF TREATMENTS IN AN OUTCOMES-BASED RISK-SHARING SCHEME IN FINLAND

 

Asseburg C1, Soini EJ1, Taiha M2
1ESiOR Oy, Kuopio, Finland, 2UCB Pharma Oy Finland, Espoo, Finland

PMS82

US TREATMENT PATTERNS IN PSORIATIC ARTHRITIS NEWLY INITIATED ON ETANERCEPT OR ADALIMUMAB

 

Zhang F1, Li S2, Curtis JR3
1Celgene Corporation, Summit, NJ, USA, 2Celgene Corporation, Warren, NJ, USA, 3The University of Alabama at Birmingham, Birmingham, AL, USA

SESSION III – TUESDAY, 6 NOVEMBER
SET-UP: Tuesday, 6 November 2012, 8:30 – 8:45
POSTER DISPLAY HOURS: Tuesday, 6 November 2012, 8:45 – 13:45
POSTER AUTHOR DISCUSSION HOUR: Tuesday, 6 November 2012, 12:45 – 13:45
DISMANTLE: Tuesday, 6 November 2012, 13:45

URINARY/KIDNEY DISORDERS – Clinical Outcomes Studies

PUK1

A SWEDISH PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE IMPACT IN QUALITY OF LIFE AMONG PREVIOUSLY UNTREATED PATIENTS RECEIVING THEIR FIRST PRESCRIPTION OF SOLIFENACIN. (SPOQ-STUDY)

 

Mattiason A1, Persson CA2
1Skane University Hospital, Lund, Sweden, 2Astellas Pharma, Kastrup, Denmark

PUK2

ISSUES IN THE SYSTEMATIC REVIEW OF DRUGS FOR RARE DISEASES: A CASE STUDY OF ECULIZUMAB FOR AHUS

 

Kaltenthaler E, Rathbone J, Tappenden P, Bessey A, Cantrell A
University of Sheffield, Sheffield, UK

PUK3

EVALUATION OF MEDICATION-RELATED PROBLEMS IN HEMODIALYSIS PATIENTS

 

Wu CL
Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan

URINARY/KIDNEY DISORDERS – Cost Studies

PUK4

A COST-COMPARISON ANALYSIS OF TREATING OVERACTIVE BLADDER (OAB) WITH FESOTERODINE, TOLTERODINE OR SOLIFENACIN IN DAILY CLINICAL PRACTICE IN SPAIN

 

Sicras-Mainar A1, Rejas J2, Navarro-Artieda R3, Aguado-Jodar A4, Ruiz-Torrejón A5, Kvasz MG6
1Badalona Serveis Assistencials, Badalona, Barcelona, Spain, 2Pfizer España, Alcobendas/Madrid, Spain, 3Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, 4Dirección de Atención Primaria, Consorci Sanitari Integral, Barcelona, Barcelona, Spain, 5Servicio Balear de Salud, Ib-Salut., Palma de Mallorca, Spain, 6Pfizer, Paris, France

PUK5

EMPLOYMENT RATES AND INDIRECT COSTS IN PATIENTS WITH END-STAGE RENAL DISEASE: DIFFERENCES BETWEEN MODALITIES OF RENAL REPLACEMENT THERAPY

 

Julián JC1, Cuervo J2, Rebollo P2, Castejón N2, Callejo D2
1ALCER Renal Foundation, Madrid, Spain, 2LA-SER (BAP LA-SER Outcomes), Oviedo, Asturias, Spain

PUK6

THE ECONOMIC BURDEN OF POST-TRANSPLANT EVENTS IN RENAL TRANSPLANT PATIENTS IN GERMANY (THE PORTRAIT STUDY)

 

Neumayer HH1, Lopau K2, Glander P1, Detering J2, Chamberlain G3, Naik M1, Plesnila-Frank C4, Sabater FJ5, Bennett H3, Rosz D4, Sennfalt K6
1Charite Hospital, Berlin, Germany, 2University Hospital Würzburg, Würzburg, Germany, 3Swansea University, Cardiff, UK, 4Bristol-Myers Squibb Germany, Munich, Germany, 5Bristol-Myers Squibb, Rueil-Malmaison, Paris, France, 6Bristol-Myers Squibb, Rueil-Malmaison, France

PUK7

COST OF ILLNESS OF OVERACTIVE BLADDER SYNDROME IN HUNGARY

 

Brodszky V1, Gulácsi L1, Majoros A2, Piróth C3, Böszörményi-Nagy G4, Baji P5, V. Hevér N1, Balogh O1, Péntek M1
1Corvinus University of Budapest, Budapest, Hungary, 2Semmelweis University, Budapest, Hungary, 3Jahn Ferenc South-Pest Teaching Hospital, Budapest, Hungary, 4Bajcsy-Zsilinszky Hospital, Budapest, Hungary, 5Maastricht University, Maastricht, The Netherlands

PUK8

4-YEAR INCIDENCE AND COSTS OF HOSPITALIZED COMPLICATIONS WITHIN KIDNEY TRANSPLANT PATIENTS IN FRANCE

 

Vainchtock A1, Fernandes J2, Cotté FE3, Chaize G4, Gaudin AF5
1HEVA, LYON, France, 2Oc Santé - Centre Médical Odysséum, Montpellier, France, 3Bristol-Myers Squibb, Rueil-Malmaison , France, 4HEVA, Lyon, France, 5Bristol-Myers-Squibb, Rueil Malmaison, France

PUK9

DIRECT AND INDIRECT COST OF URGE URINARY INCONTINENCE WITH AND WITHOUT PHARMACOTHERAPY

 

Goren A1, Zou KH2, Gupta S3, Chen CI2
1Kantar Health, New York, NY, USA, 2Pfizer, Inc., New York, NY, USA, 3Kantar Health, Princeton, NJ, USA

PUK10

COMPARATIVE COST-ANALYSIS OF SIX ANTICHOLINERGICS FOR THE TREATMENT OF OVERACTIVE BLADDER AND INCONTINENCE IN GERMANY

 

Mayrhofer T1, Grabe K2, Felder S3
1University of Duisburg-Essen, Essen, Germany, 2Astellas Pharma GmbH, Munich, Germany, 3University of Basel, Basel, Switzerland

PUK11

COST-EFFECTIVNESS ANALYSIS OF ONCE DAILY VERSUS TWICE DAILY TACROLIMUS IN POST-RENAL TRANSPLANT PATIENTS IN THE CZECH REPUBLIC

 

Klimes J, Vocelka M, Dolezal T, Suchanková E
Institute of Health Economics and Technology Assessment, Prague, Czech Republic

PUK12

COST-EFFECTIVENESS OF IMMUNOSUPPRESSIVE REGIMENS IN RENAL TRANSPLANT RECIPIENTS IN GERMANY: A MODEL UPDATE

 

Jürgensen JS1, Greiner RA2, Hösel V3, Ikenberg R4, Schiffner-Rohe J5
1Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, 2IMS Health GmbH & Co. OHG, München, Germany, 3StatSciConsult, München, Germany, 4IMS Health GmbH & Co. OHG, München, Germany, 5Pfizer Deutschland GmbH, Berlin, Germany

PUK13

COST-EFFECTIVENESS OF KETOSTERIL TREATMENT IN DIALYSIS PATIENTS

 

Tóth E1, Nagy B2
1Healthware Consulting Ltd., Budapest, Hungary, 2Healthware Ltd, Budapest, Hungary

PUK14

COST-EFFECTIVENESS ANALYSIS OF MIRABEGRON VERSUS TOLTERODINE EXTENDED RELEASE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN THE UNITED STATES

 

Xie J1, Zhou ZY2, Bui CN3, Yan Y1, De G1, Runken MC4, Wu EQ2
1Analysis Group, Inc., New York, NY, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Astellas Pharma US, Inc., Northbrook, IL, USA, 4Astellas Pharma US, Inc., Glenview, IL, USA

PUK15

SEVELAMER IN EARLY STAGES NONDIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) DOMINATES CALCIUM CARBONATE THROUGH REDUCTION OF DEATHS AND HOSPITALIZATIONS

 

Ruggeri M1, di Iorio B2
1Università Cattolica del Sacro Cuore, rome, Italy, 2Ospedale Landolfi, Avellino, Italy

PUK16

COST-EFFECTIVENESS OF KETOSTERIL TREATMENT IN STAGE 3-4 CKD PATIENTS

 

Tóth E1, Bacskai M1, Nagy B2, Lang Z1
1Healthware Consulting Ltd., Budapest, Hungary, 2Healthware Ltd, Budapest, Hungary

PUK17

COST-MIMIMIZATION ANALYSIS OF PAZOPANIB VERSUS SUNITINIB, SORAFENIB AND BEVACIZUMAB+ INTERFERON á-2A FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

 

Sura M1, Goryaynov S2, Avxentyeva M3, Omelyanovsky V3
1Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, RNRMU named after N.I. Pirogov, Moscow , Russia, 2Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, RNRMU named after N.I. Pirogov, Moscow, Russia, 3Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National Research Medical University, Moscow, Russia

PUK18

COST-EFFECTIVENESS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN NON-DIABETIC ADVANCED RENAL DISEASE – A DUTCH PERSPECTIVE

 

Adarkwah CC1, Gandjour A2, Akkerman M3, Evers SM1
1Maastricht University, Maastricht, The Netherlands, 2Frankfurt School for Finance & Management, Frankfurt a. M., LA, Germany, 3RWTH University Aachen, Aachen, Germany

URINARY/KIDNEY DISORDERS – Patient-Reported Outcomes & Patient Preference Studies

PUK19

ANTIMUSCARINIC PERSISTENCE PATTERNS IN NEWLY TREATED PATIENTS WITH OVERACTIVE BLADDER (OAB): RETROSPECTIVE COMPARATIVE ANALYSIS OF FESOTERODINE, SOLIFENACIN AND TOLTERODINE

 

Sicras-Mainar A1, Rejas J2, Navarro-Artieda R3, Ruiz-Torrejón A4, Aguado-Jodar A5, Kvasz MG6
1Badalona Serveis Assistencials, Badalona, Barcelona, Spain, 2Pfizer España, Alcobendas/Madrid, Spain, 3Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, 4Servicio Balear de Salud, Ib-Salut., Palma de Mallorca, Spain, 5Dirección de Atención Primaria, Consorci Sanitari Integral, Barcelona, Barcelona, Spain, 6Pfizer, Paris, France

PUK20

DEVELOPMENT OF A PATIENT ADHERENCE SPECIFIC SCALE FOR USE IN THE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA PATIENTS

 

Amarenco G1, Haab F1, Benjamin L2, Slama A2, Dias Barbosa C3, Ruttkay Y3, Bergmann JF4
1Hôpital Tenon, Paris, France, 2GlaxoSmithKline, Marly le Roi, France, 3MAPI Consultancy, Lyon, France, 4Hôpital Lariboisière, Paris, France

PUK21

CONVERSION FROM EPOETIN ALFA TO DARBEPOETIN ALFA IN HEMODIALYSIS PATIENTS WITH CHRONIC KIDNEY DISEASE: FRENCH MONOCENTRE OBSERVATIONAL STUDY

 

Binaut R1, Bacri JL1, Fleury D1, Maisonneuve N1, Labatut D1, Lemaitre V1, Medeghri Z2, Bir G2, Lanier J2
1Valenciennes Hospital, Valenciennes, France, 2Amgen SAS, Neuilly-sur-Seine, France

URINARY/KIDNEY DISORDERS – Health Care Use & Policy Studies

PUK22

EVALUATING THE MINIMUM RENAL ALLOGRAFT SURVIVAL TIME REQUIRED FOR TRANSPLANTATION TO REMAIN COST SAVING IN THE UNITED KINGDOM

 

McEwan P1, Lebmeier M2
1HEOR Consulting, Monmouth, Monmouthshire, UK, 2Bristol-Myers Squibb Company, Uxbridge, Middlesex, UK

PUK23

BURDEN OF CHRONIC KIDNEY DISEASE IN GERMAN DIABETES PATIENTS, A SYSTEMATIC LITERATURE REVIEW AND DATA GAP ANALYSIS

 

Korolewa V1, Hengst N2, Wolff M2, Berger K3, Ehlken B4, Eheberg D5
1Abbott GmbH & Co. KG, Wiesbaden, Germany, 2Abbott GmbH & Co. KG, Ludwigshafen, Germany, 3IMS, Munich, Germany, 4IMS Health, Munich, Germany, 5IMS Health GmbH & Co. OHG, Munich, Germany

PUK24

PHARMACOECONOMIC ASPECTS OF USE OF ERYTHROPOIETIN DRUGS IN PATIENTS ON HEMODIALYSIS IN UKRAINE

 

Bezditko N1, Iakovlieva L1, Mishchenko O1, Gerasymova O1, Kyrychenko O2
1National University of Pharmacy, Kharkiv, Ukraine, 2National University of Pharmacy, Kharkiv , Ukraine

PUK25

PATTERNS OF TREATMENT FAILURE AMONG PATIENTS RECEIVING ANTICHOLINERGICS FOR OVERACTIVE BLADDER (OAB) TREATED IN A MANAGED CARE SETTING

 

Chancellor M1, Bruno A2, Corbell C3, Zaharson T3, Bramley T2, Globe D3
1Beaumont Hospital, Royal Oak, MI, USA, 2Xcenda, LLC, Palm Harbor, FL, USA, 3Allergan, Inc., Irvine, CA, USA



15th Annual European Congress Index Page